<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancers (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Cancers (Basel)</journal-id><journal-id journal-id-type="publisher-id">cancers</journal-id><journal-title-group><journal-title>Cancers</journal-title></journal-title-group><issn pub-type="epub">2072-6694</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6895828</article-id><article-id pub-id-type="doi">10.3390/cancers11111668</article-id><article-id pub-id-type="publisher-id">cancers-11-01668</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Transcription Factor and miRNA Interplays Can Manifest the Survival of ccRCC Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Qin</surname><given-names>Shijie</given-names></name></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Xuejia</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Canbiao</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jin</surname><given-names>Ping</given-names></name><xref rid="c1-cancers-11-01668" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Fei</given-names></name><xref rid="c1-cancers-11-01668" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-cancers-11-01668">Laboratory for Comparative Genomics and Bioinformatics, College of Life Science, Nanjing Normal University, Nanjing 210046, China; <email>191201005@stu.njnu.edu.cn</email> (S.Q.); <email>181202063@stu.njnu.edu.cn</email> (X.S.); <email>191202061@stu.njnu.edu.cn</email> (C.W.)</aff><author-notes><corresp id="c1-cancers-11-01668"><label>*</label>Correspondence: <email>jinping@njnu.edu.cn</email> (P.J.); <email>mafei01@tsinghua.org.cn</email> (F.M.)</corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2019</year></pub-date><volume>11</volume><issue>11</issue><elocation-id>1668</elocation-id><history><date date-type="received"><day>28</day><month>9</month><year>2019</year></date><date date-type="accepted"><day>24</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Clear cell renal cell carcinoma (ccRCC) still remains a higher mortality rate in worldwide. Obtaining promising biomakers is very crucial for improving the diagnosis and prognosis of ccRCC patients. Herein, we firstly identified eight potentially prognostic miRNAs (hsa-miR-144-5p, hsa-miR-223-3p, hsa-miR-365b-3p, hsa-miR-3613-5p, hsa-miR-9-5p, hsa-miR-183-5p, hsa-miR-335-3p, hsa-miR-1269a). Secondly, we found that a signature containing these eight miRNAs showed obviously superior to a single miRNA in the prognostic effect and credibility for predicting the survival of ccRCC patients. Thirdly, we discovered that twenty-two transcription factors (TFs) interact with these eight miRNAs, and a signature combining nine TFs (<italic>TFAP2A</italic>, <italic>KLF5</italic>, <italic>IRF1</italic>, <italic>RUNX1</italic>, <italic>RARA</italic>, <italic>GATA3</italic>, <italic>IKZF1</italic>, <italic>POU2F2</italic>, and <italic>FOXM1</italic>) could promote the prognosis of ccRCC patients. Finally, we further identified eleven genes (hsa-miR-365b-3p, hsa-miR-223-3p, hsa-miR-1269a, hsa-miR-144-5p, hsa-miR-183-5p, hsa-miR-335-3p, <italic>TFAP2A</italic>, <italic>KLF5</italic>, <italic>IRF1</italic>, <italic>MYC</italic>, <italic>IKZF1</italic>) that could combine as a signature to improve the prognosis effect of ccRCC patients, which distinctly outperformed the eight-miRNA signature and the nine-TF signature. Overall, we identified several new prognosis factors for ccRCC, and revealed a potential mechanism that TFs and miRNAs interplay cooperatively or oppositely regulate a certain number of tumor suppressors, driver genes, and oncogenes to facilitate the survival of ccRCC patients.</p></abstract><kwd-group><kwd>ccRCC</kwd><kwd>prognostic biomarker</kwd><kwd>miRNA</kwd><kwd>transcription factor</kwd><kwd>interplay</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-cancers-11-01668"><title>1. Introduction</title><p>Clear cell renal cell carcinoma (ccRCC) is the most common malignant tumor subtype of kidney cancer [<xref rid="B1-cancers-11-01668" ref-type="bibr">1</xref>], which still remains a higher mortality rate in worldwide [<xref rid="B2-cancers-11-01668" ref-type="bibr">2</xref>]. At present, the main treatment method on ccRCC patients is early resection, but its curative effect and prognosis are not very good for these terminally ccRCC patients [<xref rid="B3-cancers-11-01668" ref-type="bibr">3</xref>]. Currently, above 30&#x02013;50% of ccRCC patients have missed the best surgical opportunity due to the lack of early clinical symptoms [<xref rid="B3-cancers-11-01668" ref-type="bibr">3</xref>]. Therefore, acquiring new molecular biomarkers not only are urgently needed for establishing clinically stratifying system to improve the diagnostic efficiency of ccRCC patients, but are of great clinical value for effectively improving the management and treatment strategy of ccRCC patients. </p><p>MicroRNAs (miRNAs), a class of small noncoding RNAs with about 22 nucleotides, can negatively regulate gene expression at the post-transcriptional level by influencing the mRNA degradation and/or translational efficiency involved in manifold biological processes [<xref rid="B4-cancers-11-01668" ref-type="bibr">4</xref>,<xref rid="B5-cancers-11-01668" ref-type="bibr">5</xref>,<xref rid="B6-cancers-11-01668" ref-type="bibr">6</xref>,<xref rid="B7-cancers-11-01668" ref-type="bibr">7</xref>]. In recent years, many studies have revealed that miRNAs not only can act as oncogenes or tumor suppressor genes involve in tumorigenesis and progressions of various cancers [<xref rid="B8-cancers-11-01668" ref-type="bibr">8</xref>], but can serve as valuable boimarkers for the detection and prognosis of cancer patients [<xref rid="B9-cancers-11-01668" ref-type="bibr">9</xref>,<xref rid="B10-cancers-11-01668" ref-type="bibr">10</xref>,<xref rid="B11-cancers-11-01668" ref-type="bibr">11</xref>,<xref rid="B12-cancers-11-01668" ref-type="bibr">12</xref>,<xref rid="B13-cancers-11-01668" ref-type="bibr">13</xref>,<xref rid="B14-cancers-11-01668" ref-type="bibr">14</xref>,<xref rid="B15-cancers-11-01668" ref-type="bibr">15</xref>]. Thus, the current study has been focused on finding novel miRNAs as effective prognostic predictors for the overall survival of cancer patients [<xref rid="B16-cancers-11-01668" ref-type="bibr">16</xref>,<xref rid="B17-cancers-11-01668" ref-type="bibr">17</xref>,<xref rid="B18-cancers-11-01668" ref-type="bibr">18</xref>,<xref rid="B19-cancers-11-01668" ref-type="bibr">19</xref>,<xref rid="B20-cancers-11-01668" ref-type="bibr">20</xref>]. </p><p>At present, some studies have suggested that a lot of miRNAs could act as oncogenic miRNAs or tumor suppressor miRNAs to participate in the tumorigenesis and progressions of ccRCC, and they might serve as diagnosic and prognosic biomarkers for ccRCC patients [<xref rid="B21-cancers-11-01668" ref-type="bibr">21</xref>,<xref rid="B22-cancers-11-01668" ref-type="bibr">22</xref>,<xref rid="B23-cancers-11-01668" ref-type="bibr">23</xref>,<xref rid="B24-cancers-11-01668" ref-type="bibr">24</xref>]. However, several studies have shown that some miRNAs may play complete contradictor roles in diagnosic and prognosic effects for ccRCC, such as miR-99a [<xref rid="B25-cancers-11-01668" ref-type="bibr">25</xref>,<xref rid="B26-cancers-11-01668" ref-type="bibr">26</xref>], miR-106a [<xref rid="B27-cancers-11-01668" ref-type="bibr">27</xref>,<xref rid="B28-cancers-11-01668" ref-type="bibr">28</xref>], miR-125b [<xref rid="B21-cancers-11-01668" ref-type="bibr">21</xref>,<xref rid="B29-cancers-11-01668" ref-type="bibr">29</xref>], miR-144 [<xref rid="B30-cancers-11-01668" ref-type="bibr">30</xref>,<xref rid="B31-cancers-11-01668" ref-type="bibr">31</xref>], miR-203 [<xref rid="B32-cancers-11-01668" ref-type="bibr">32</xref>,<xref rid="B33-cancers-11-01668" ref-type="bibr">33</xref>], and miR-378 [<xref rid="B34-cancers-11-01668" ref-type="bibr">34</xref>,<xref rid="B35-cancers-11-01668" ref-type="bibr">35</xref>], which might greatly limit their applications into the clinical diagnosis and prognosis for ccRCC patients. Therefore, we should further study the functional roles of miRNAs as potentially diagnostic and prognostic biomarkers for ccRCC, whilst it is also very necessary for expanding the screening of new reliable miRNAs as diagnostic and prognostic biomarkers for ccRCC. </p><p>Nowadays, a number of studies are mainly focused on the fuctional mechanism of miRNAs that regulate their targets to cause the occurrence and development of ccRCC. However, how are miRNAs themselves regulated in the occurrence of ccRCC, which is still largely unknown. Intriguingly, currently, many studies have shown that transcription factors (TFs) can regulate miRNA expressions, and miRNAs may also regulate TF expressions in gene regulatory networks [<xref rid="B36-cancers-11-01668" ref-type="bibr">36</xref>,<xref rid="B37-cancers-11-01668" ref-type="bibr">37</xref>,<xref rid="B38-cancers-11-01668" ref-type="bibr">38</xref>,<xref rid="B39-cancers-11-01668" ref-type="bibr">39</xref>], and TFs and miRNAs interplay could precisely modulate gene expressions to maintain cell homeostasis [<xref rid="B37-cancers-11-01668" ref-type="bibr">37</xref>,<xref rid="B40-cancers-11-01668" ref-type="bibr">40</xref>,<xref rid="B41-cancers-11-01668" ref-type="bibr">41</xref>]. Therefore, considering the complexity of TFs and miRNAs interplay mediating gene expression, substantial works should be further made in elucidating the mechanism that TFs and miRNAs interplay drives the occurrence and development of ccRCC, and finding TFs and miRNAs as novel diagnostic and prognostic biomarkers in the survival of ccRCC patients.</p><p>Considering that miRNAs often carry out their functions through fine-tuning the expression of their target genes, and multiple miRNAs can also synergistically or antagonistically regulate one or more target genes to control the strength and duration of cell response [<xref rid="B42-cancers-11-01668" ref-type="bibr">42</xref>,<xref rid="B43-cancers-11-01668" ref-type="bibr">43</xref>]. Here, we firstly screened eight potentially prognostic miRNAs based on RNA-seq and clinical information from the TCGA database. We next combined the eight miRNAs as an integrative prognostic predictor to evaluate the prognostic efficiency. This result showed that the prognostic efficiency and credibility of the eight-miRNA signature significantly outperformed a single miRNA, which implies that the synergistical regulation of miRNAs plays key roles in the tumorigenesis and progression of ccRCC. Subsequently, we utilized target prediction software and KEGG enrichment analysis to find that these eight miRNAs mainly control a certain number of oncogenic and onco-suppressive genes from some crucially cancer-related pathways improving the survival of ccRCC patients. Additionally, we found that twenty-two TFs could interact with eight miRNAs based on deepCAGE, TransmiR v2.0, and MirWalk3.0 database [<xref rid="B44-cancers-11-01668" ref-type="bibr">44</xref>,<xref rid="B45-cancers-11-01668" ref-type="bibr">45</xref>,<xref rid="B46-cancers-11-01668" ref-type="bibr">46</xref>]. To further reveal the possible molecular mechanism that TFs and miRNAs interplay facilitates the survival of ccRCC patients, we further constructed a interplay network of TFs and miRNAs and the network analysis revealed that the interplay between twenty-two TFs and eight miRNAs could synergistically control the expression of oncogenes, driver genes, and tumor suppressor genes to involve in the regulation of tumorigenesis and progression of ccRCC. Finally, we performed cox regression analysis to identify eleven genes as a eleven-gene signature, including six miRNAs and five TFs and the prognostic effect and the credibility of the eleven-gene signature also obviously outperformed the eight-miRNA signature and the nine-TF signature. Taken together, our findings not only revealed a novel possible mechanism that TFs and miRNAs interplay could regulate cooperatively oncogenes, driver genes, and tumor suppressor genes to facilitate the survival of ccRCC patients, but also identified some new potential prognostic factors and therapeutic targets for ccRCC patients. </p></sec><sec sec-type="results" id="sec2-cancers-11-01668"><title>2. Results</title><sec id="sec2dot1-cancers-11-01668"><title>2.1. Identification of miRNAs as Potential Prognostic Biomarkers</title><p>In this work, we found 110 differentially expressed miRNAs between 480 ccRCC tissues and 68 paracancerous tissues, including 50 up-regulated and 60 down-regulated miRNAs (<xref ref-type="app" rid="app1-cancers-11-01668">Figure S1A</xref>). Here, to identify these prognostic miRNAs for predicting the overall survival in ccRCC patients, we grouped 480 patients with at least 90 days into high- and low-expression groups according to the median expression level of each of 110 differentially expressed miRNAs. We next performed survival analysis to find that 37 miRNAs might be associated with the survival of ccRCC patients (<italic>p</italic>-value &#x0003c; 0.05) (<xref ref-type="app" rid="app1-cancers-11-01668">Table S1</xref>). Next, we performed univariate analysis and screened these top 21 miRNAs with a <italic>p</italic>-value &#x0003c; 0.001 (<xref ref-type="fig" rid="cancers-11-01668-f001">Figure 1</xref>, <xref ref-type="app" rid="app1-cancers-11-01668">Table S2</xref>) for multivariate stepwise cox regression analysis to further determine independently prognostic miRNA biomarkers for ccRCC patients. We finally obtained eight potential prognostic miRNAs, including four down-regulated miRNAs (hsa-miR-9-5p, hsa-miR-1269a, hsa-miR-183-5p, hsa-miR-335-3p) and four up-regulated miRNAs (hsa-miR-365b-3p, hsa-miR-223-3p, hsa-miR-144-5p, hsa-miR-3613-5p), which might be involved in the survival of ccRCC patients. We divided 480 ccRCC patients into high-risk and low-risk groups according to the median univariate cox risk score of each of these eight miRNAs to further detect the association between these identified eight miRNAs and the overall survival of ccRCC patients. Kaplan-Meier survival analysis and log-rank test indicated that, in all eight independent miRNA cohorts, ccRCC patients with high-risk groups exhibited the overall survival more badly than low-risk groups (all cohorts <italic>p</italic>-value &#x0003c; 0.01) (<xref ref-type="app" rid="app1-cancers-11-01668">Figure S2</xref>). Interestingly, the range of the AUC value for eight miRNAs was about 0.6~0.7 (<xref ref-type="app" rid="app1-cancers-11-01668">Figure S3</xref>), which indicated that the established prognosis model has a very good prognosis effect. Overall, these findings suggested that any of eight miRNAs might act as a possible prognostic biomarker for the survival of ccRCC patients.</p></sec><sec id="sec2dot2-cancers-11-01668" sec-type="subjects"><title>2.2. The Exprssion Level of Eight Prognostic miRNAs is Associated with the Survival of ccRCC Patients</title><p>To explore whether the eight miRNAs could be used as potential diagnostic biomarkers for distinguishing patients with ccRCC from controls. Here, we used survival curves to assess the association between the expression level of these eight miRNAs and the overall survival of ccRCC patients. We divided ccRCC patients into high-expression and low-expression miRNA groups according to the median expression level of each of these eight miRNAs. This result indicated that, in all eight independent miRNA cohorts, ccRCC patients with high-expression miRNA groups exhibited a worse overall survival rate than the low-expression miRNA groups, except for hsa-miR-144-5p (<xref ref-type="fig" rid="cancers-11-01668-f002">Figure 2</xref>). These results seemed to indicate that these highly expressed hsa-miR-9-5p, hsa-miR-1269a, hsa-miR-183-5p, hsa-miR-335-3p, hsa-miR-365b-3p, hsa-miR-223-3p, and hsa-miR-3613-5p might be associated with a poor prognosis for ccRCC patients. It is noteworthy that the highly expressed hsa-miR-144-5p was associated with better overall survival (<xref ref-type="fig" rid="cancers-11-01668-f002">Figure 2</xref>), which suggested that hsa-miR-144-5p should be a good prognostic factor for ccRCC patients. In addition, we further calculated the association between the expression level of eight miRNAs and patient&#x02019;s clinical diagnostic factors, respectively. Our results showed that eight prognostic miRNAs were significantly associated with T stage, M stage, G stage, and pathologic stage (<xref ref-type="app" rid="app1-cancers-11-01668">Figure S4</xref>, <xref ref-type="app" rid="app1-cancers-11-01668">Table S3</xref>), implying that these eight miRNAs might be involved in tumorigenesis and progression of ccRCC and could be served as prognostic biomarkers for the survival of ccRCC patients. </p></sec><sec id="sec2dot3-cancers-11-01668" sec-type="subjects"><title>2.3. Prognostic Value of Combined Eight miRNAs as a Signature in ccRCC Patients</title><p>Considering multiple miRNAs could synergistically or antagonistically regulate one or more target genes to control cell fate. Herein, we further combined these eight miRNAs as an integrative prognostic predictor. The 480 patients were divided into low-risk group and high-risk group and then subjected to survival analysis. Our results showed that there was a significant difference in the overall survival between the two risk groups, and the high-risk group had more worse overall survival than the low-risk group (<italic>p</italic> &#x0003c; 0.0001, <xref ref-type="fig" rid="cancers-11-01668-f003">Figure 3</xref>A). In addition, the ROC curve based on the eight-miRNA signature also, respectively, showed an average 3, 5, and 10 year AUC for 0.762, 0.747, and 0.746 (<xref ref-type="fig" rid="cancers-11-01668-f003">Figure 3</xref>B). Interestingly, the concordance index (0.7305) of the combined prognostic model of the eight-miRNA signature was higher than that of all single miRNA (<xref ref-type="app" rid="app1-cancers-11-01668">Table S4</xref>), whereas the Akaike information criterion (1622.2491) of the combined prognostic model of the eight-miRNA signature was lower than that of all single miRNA (<xref ref-type="app" rid="app1-cancers-11-01668">Table S4</xref>), which indicated that the prognostic effect and credibility of the eight-miRNA signature were clearly superior to all single miRNA. These findings suggested that the eight-miRNA signature could act as a prognostic biomarker for promoting the survival of ccRCC patients. </p><p>Cox proportional hazard regression analysis was further used to characterize the impact of various clinical factors on the overall survival of ccRCC patients (<xref rid="cancers-11-01668-t001" ref-type="table">Table 1</xref>). Age, gender, tumor size, metastasis, pathologic stage, neoplasm histologic grade, and the combined eight miRNAs signature were coded as continuous variables. As shown in <xref rid="cancers-11-01668-t001" ref-type="table">Table 1</xref>, the univariate analysis showed that all factors, except for gender, might act as prognostic indicators for ccRCC patients. However, the multivariate analysis indicated that only age and the eight-miRNA signature can be used as independent prognostic indicators for ccRCC patients. This result revealed that the eight-miRNA signature could not only could serve as an independent prognostic factor for overall survival of ccRCC patients, but also act as an effective risk stratification indicator for ccRCC patient diagnosis. </p></sec><sec id="sec2dot4-cancers-11-01668"><title>2.4. Function Roles of Eight Prognostic miRNAs in ccRCC </title><p>To reveal the functional role of eight prognostic miRNAs in ccRCC, we first identified 3672 differentially expressed genes between 480 ccRCC tissues and 68 paracancerous tissues, including 2057 up-regulated genes (of which 116 transcription factors) and 1012 down-regulated genes (of which 61 transcription factors) (<xref ref-type="app" rid="app1-cancers-11-01668">Figure S1B</xref>). Next, we obtained 357 down-regulated targets of 4 up-regulated miRNAs (hsa-miR-365b-3p, hsa-miR-223-3p, hsa-miR-144-5p, hsa-miR-3613-5p) and 1012 up-regulated targets of 4 down-regulated miRNAs (hsa-miR-9-5p, hsa-miR-1269a, hsa-miR-183-5p, hsa-miR-335-3p). </p><p>To elucidate the function of these target genes of these eight miRNAs in ccRCC, we further performed KEGG pathway analysis using clusterProfiler R package. We found that these significantly up-regulated target genes of four down-regulated miRNAs were widely involved in cancer-related signaling pathways, such as MAPK, Ras, NF-kappa B, Chemokine and Cytokine-cytokine receptor (<xref ref-type="app" rid="app1-cancers-11-01668">Figure S5A</xref>). These results suggested that the interplay among multiple signaling pathways might synergistically mediate the occurrence and development of ccRCC. </p><p>We further picked out these up-regulated target genes of four down-regulated miRNAs from these main cancer signaling pathways to construct the miRNA-gene regulation network (<xref ref-type="fig" rid="cancers-11-01668-f004">Figure 4</xref>A). As shown in <xref ref-type="fig" rid="cancers-11-01668-f004">Figure 4</xref>A, some up-regulated target genes were regulated by more than one down-regulated miRNA, implying that the cooperative regulation of multiple miRNAs might play key roles in the initiation and progression of ccRCC. In addition, the protein-protein interaction (PPI) network was also constructed for these up-regulated target genes of four down-regulated miRNAs using the STRING database, which demonstrated a close interaction within these target genes (<xref ref-type="fig" rid="cancers-11-01668-f004">Figure 4</xref>B). Here, a node with &#x02265; 20 degrees is defined as a hub gene, thus we found 30 hub genes (<xref ref-type="app" rid="app1-cancers-11-01668">Table S5</xref>). We next used multivariate cox regression analysis for 30 hub genes to further select prognosis-related genes for ccRCC patients. We found ten potential prognostic genes, including eight tumor suppressor and/or driver genes (<italic>VEGFA</italic>, <italic>CCND1</italic>, <italic>BAX</italic>, <italic>IL7R</italic>, <italic>SHC1</italic>, <italic>FLT1</italic>, <italic>IL7,</italic> and <italic>JAK3</italic>) [<xref rid="B47-cancers-11-01668" ref-type="bibr">47</xref>,<xref rid="B48-cancers-11-01668" ref-type="bibr">48</xref>,<xref rid="B49-cancers-11-01668" ref-type="bibr">49</xref>,<xref rid="B50-cancers-11-01668" ref-type="bibr">50</xref>,<xref rid="B51-cancers-11-01668" ref-type="bibr">51</xref>], as well as two chemokines (<italic>CXCL9</italic> and <italic>CXCL10</italic>) [<xref rid="B50-cancers-11-01668" ref-type="bibr">50</xref>]. Additionally, we combined the above ten hub genes as a signature to perform survival analysis. The result indicated that the low-risk group has a better overall survival rate than the high-risk group (<italic>p</italic> &#x0003c; 0.0001, <xref ref-type="fig" rid="cancers-11-01668-f004">Figure 4</xref>C), whilst the ROC curve also demonstrated that the ten-hub gene signature had a better prognostic effect and credibility for ccRCC patients with an average 3, 5 and 10 year AUC for 0.728, 0.751 and 0.796, respectively (<xref ref-type="fig" rid="cancers-11-01668-f004">Figure 4</xref>D). Taken together, our present findings suggested a possible molecular mechanism that the down-regulated expressed hsa-miR-9-5p, hsa-miR-1269a, hsa-miR-183-5p, and hsa-miR-335-3p might cooperatively up-regulate the expression level of numerous tumor suppressor and/or driver genes from some cancer-related pathways to improve the overall survival of ccRCC patients.</p><p>Compared to four down-regulated miRNAs, these down-regulated target genes of four up-regulated miRNAs were less enriched in cancer-associated signaling pathways (<xref ref-type="app" rid="app1-cancers-11-01668">Figure S5B</xref>). However, we further analyzed these target genes of three up-regulated miRNAs (hsa-miR-365b-3p, hsa-miR-223-3p, hsa-miR-3613-5p), finding that many genes of their target genes are involved in some cancer-associated signaling pathways (<xref ref-type="fig" rid="cancers-11-01668-f005">Figure 5</xref>A). Therefore, here, we reused multivariate cox regression analysis to screen potential prognostic genes for ccRCC patients. The result showed that five genes (<italic>PRKCA</italic>, <italic>ADORA1</italic>, <italic>PPARGC1A</italic>, <italic>KL</italic>, <italic>GNG7</italic>) could be identified as potentially prognostic factors, and they have also been suggested as tumor suppressor genes [<xref rid="B49-cancers-11-01668" ref-type="bibr">49</xref>]. Interestingly, the survival analysis indicated that the five-gene signature could significantly stratify ccRCC patients into a high- and low-risk group (<italic>p</italic> &#x0003c; 0.0001, <xref ref-type="fig" rid="cancers-11-01668-f005">Figure 5</xref>B), and the AUC value of an average 3, 5 and 10 year is 0.696, 0.698, and 0.708, respectively (<xref ref-type="fig" rid="cancers-11-01668-f005">Figure 5</xref>C). Overall, we proposed a possibly functional mechanism that three highly expressed miRNAs (hsa-miR-365b-3p, hsa-miR-223-3p, and hsa-miR-3613-5p) might synergistically down-regulate the expression of many tumor suppressor genes to decrease the survival of ccRCC patients. </p><p>Interestingly, our above results have indicated that the highly expressed hsa-miR-144-5p could act as a good prognostic factor for ccRCC patients. How does the highly expressed hsa-miR-144-5p facilitate the survival of ccRCC patients? Thus, we carried out a in-depth analysis for these target genes of hsa-miR-144-5p. Intriguingly, we found that hsa-miR-144-5p could regulate 55 genes, and, in particular, twelve genes of them have been reported as oncogenes or driver genes (<xref ref-type="app" rid="app1-cancers-11-01668">Table S6</xref>) [<xref rid="B49-cancers-11-01668" ref-type="bibr">49</xref>]. Thus, we further used multivariate cox regression analysis for twelve oncogenes and driver genes to screen potential prognostic factors for ccRCC patients. Consequently, these five genes (<italic>MAGI3</italic>, <italic>CDKL1</italic>, <italic>CDH1</italic>, <italic>PPM1K</italic>, <italic>MSI2</italic>) could be served as potential prognostic factors. We further combined the five genes as an integrative prognostic predictor for survival analysis. These results showed that the high-risk group had a worse overall survival than the low-risk group (<italic>p</italic> &#x0003c; 0.0001, <xref ref-type="fig" rid="cancers-11-01668-f006">Figure 6</xref>A), and the AUC value of an average 3, 5 and 10 year is 0.659, 0.676 and 0.759, respectively, based on the ROC curve (<xref ref-type="fig" rid="cancers-11-01668-f006">Figure 6</xref>B). Collectively, our present findings implied that the highly expressed hsa-miR-144-5p might facilitate the overall survival of ccRCC patients through down-regulating the expression level of some certain oncogenes and/or driver genes. </p></sec><sec id="sec2dot5-cancers-11-01668"><title>2.5. The Interplay Network Between Twenty-Two TFs and Eight miRNAs </title><p>To explore the interplay between TFs and eight prognostic miRNAs, we further used TransmiR2.0 to predict these TFs that may regulate the eight prognostic miRNAs. Here, we found six down-regulated TFs (KLF5, SREBF2, TFAP2A, HIF1A, GATA3, and GATA2), which could regulate three down-regulated miRNAs (hsa-miR-9-5p, hsa-miR-183-5p, and hsa-miR-335-3p), but no TF was found for regulating hsa-miR-1269a (<xref ref-type="app" rid="app1-cancers-11-01668">Figure S6A</xref>). Whilst, 16 up-regulated TFs (CEBPA, E2F1, FOXM1, FLI1, HEY1, IKZF1, IRF1, MEF2C, MYC, POU2F2, POU5F1, PRDM1, RARA, RUNX1, RUNX3, and TCF4) were also found to regulate four up-regulated miRNAs (hsa-miR-365b-3p, hsa-miR-223-3p, hsa-miR-144-5p, hsa-miR-3613-5p) (<xref ref-type="app" rid="app1-cancers-11-01668">Figure S6B</xref>). Furthermore, we also predicted these twenty-two TFs regulated by the eight prognostic miRNAs. These detailed TF-miRNA regulatory pairs were outlined in the <xref ref-type="app" rid="app1-cancers-11-01668">Table S7</xref>. Based on the TF-miRNA pairs, we further constructed a TF-miRNA interplay network (<xref ref-type="fig" rid="cancers-11-01668-f007">Figure 7</xref>), which showed that these up-regulated TFs, such as MYC, IKZF1, and IRF1 could up-regulate the expression level of hsa-miR-223-3p and hsa-miR-365b-3p to inhibit the expression of some TFs, such as GATA2 and SREBF2, then reducing the expression of hsa-miR-183-5p and hsa-miR-335-3p to up-regulate tumor suppressor gene expression (<xref ref-type="fig" rid="cancers-11-01668-f007">Figure 7</xref>). Whilst these down-regulated TFs, such as KLF5, SREBF2, TFAP2A, HIF1A, GATA3, and GATA2, could also down-regulate the expression level of hsa-miR-9-5p, hsa-miR-183-5p, and hsa-miR-335-3p to up-regulate their target TF expression, such as E2F1, RUNX1, and RUNX3, and then up-regulated the expression of hsa-miR-365b-3p, hsa-miR-223-3p, hsa-miR-144-5p, and hsa-miR-3613-5p to down-regulate the expression of some tumor suppressor genes or oncogenes (<xref ref-type="fig" rid="cancers-11-01668-f007">Figure 7</xref>). Specially, TF and miRNA carry out opposing functions. Therefore, our study seemed to imply that the interplay between twenty-two TFs and eight prognostic miRNAs might precisely control the expression of oncogenes, driver genes, and tumor suppressor genes to facilitate the survival of ccRCC patients.</p></sec><sec id="sec2dot6-cancers-11-01668" sec-type="subjects"><title>2.6. Prognostic Value of the Combined Nine TFs as a Signature in ccRCC Patients</title><p>Based on these above results, we further used multivariate cox regression analysis for these above twenty-two TFs to determine independent prognostic TFs for ccRCC patients. Herein, we identified nine potential prognostic TFs (<italic>TFAP2A</italic>, <italic>KLF5</italic>, <italic>IRF1</italic>, <italic>RUNX1</italic>, <italic>RARA</italic>, <italic>GATA3</italic>, <italic>IKZF1</italic>, <italic>POU2F2,</italic> and <italic>FOXM1</italic>) that could act as prognostic factors for ccRCC patients. We next combined these nine TFs as a signature to detect the prognostic effect for ccRCC patients. The 480 patients were divided into low-risk group and high-risk group and subjected to survival analysis. Our results showed that the high-risk group had worse overall survival than the low-risk group (<italic>p</italic> &#x0003c; 0.0001, <xref ref-type="fig" rid="cancers-11-01668-f008">Figure 8</xref>A). In addition, the ROC curve based on the nine-TF pool also, respectively, showed an average 3, 5, and 10 year AUC for 0.721, 0.748, and 0.780 (<xref ref-type="fig" rid="cancers-11-01668-f008">Figure 8</xref>B), indicating that the nine-TF signature had very good prognosis effect and credibility for the survival of ccRCC patients. These findings suggested that the nine-TF signature could serve as a prognostic biomarker for improving the survival of ccRCC patients.</p></sec><sec id="sec2dot7-cancers-11-01668" sec-type="subjects"><title>2.7. Clinical Value of TFs and miRNAs Interplay as a Prognostic Signature in ccRCC Patients </title><p>To further reveal the role of the interaction between TFs and miRNAs in the overall survival of ccRCC patients, we hypothesized that the interaction between TFs and miRNAs is likely to improve prognosis. Thus, we next performed multivariate analysis for above twenty-two TFs and eight miRNAs to identify prognostic TFs and miRNAs for ccRCC patients. We ultimately screened eleven potential prognostic factors, including hsa-miR-365b-3p, hsa-miR-223-3p, hsa-miR-1269a, hsa-miR-144-5p, hsa-miR-183-5p, hsa-miR-335-3p, <italic>TFAP2A</italic>, <italic>KLF5</italic>, <italic>IRF1</italic>, <italic>MYC</italic>, <italic>IKZF1</italic>. We further combined the above eleven genes as a signature for survival analysis. We found that the high-risk group had worse overall survival than the low-risk group (<italic>p</italic> &#x0003c; 0.0001, <xref ref-type="fig" rid="cancers-11-01668-f009">Figure 9</xref>A). Whilst the ROC curve based on the eleven-gene signature also, respectively, showed an average 3, 5, and 10 year AUC values for 0.777, 0.771, and 0.785 (<xref ref-type="fig" rid="cancers-11-01668-f010">Figure 10</xref>B). Strikingly, the concordance index (0.7552) of the combined prognostic model of the eleven-gene signature was more higher than that of the eight-miRNA signature (0.7305) and the nine-TF signature (0.7281), and the Akaike information criterion (1606.0516) of the combined prognostic model of the eleven-gene signature was lower than that of the eight-miRNA signature (1622.2941) and the nine-TF signature (1632.5955) (<xref ref-type="app" rid="app1-cancers-11-01668">Table S8</xref>), which indicated that the prognostic effect and the credibility of the eleven-gene signature were better than both the eight-miRNA signature and the nine-TF signature did. These findings suggested that the eleven-gene signature could act as a prognostic factor for the overall survival of ccRCC patients.</p><p>Here, we also further used Cox proportional hazard regression analysis to characterize the impact of various clinical factors on overall survival of ccRCC patients (<xref rid="cancers-11-01668-t002" ref-type="table">Table 2</xref>). Age, gender, tumor-pathologic, metastasis pathologic, pathologic stage, neoplasm histologic grade, and the eleven-gene signature were coded as continuous variables. The univariate analysis showed that all factors, except for gender, might serve as prognostic indicators for ccRCC patients (<xref rid="cancers-11-01668-t002" ref-type="table">Table 2</xref>). Notably, the multivariate analysis demonstrated that only age and the eleven-gene signature could be used as independent prognostic indicators for ccRCC patients (<xref rid="cancers-11-01668-t002" ref-type="table">Table 2</xref>). Taken together, our present results revealed that the interaction between TFs and miRNAs might have very important effects on the overall survival of ccRCC patients, and the eleven-gene signature might serve as an independent factor to improve the prognosis for ccRCC patients. </p><p>Overall, herein we propose a potential molecular mechanism that the interplay between TFs and miRNAs facilitates the overall survival of ccRCC patients (<xref ref-type="fig" rid="cancers-11-01668-f010">Figure 10</xref>). On the one hand, down-regulated expressed TFs could down-regulate some miRNA expression to further up-regulate tumor suppressor gene expression, whilst the down-regulated miRNAs could also up-regulate TF expression to further up-regulate the expression of tumor suppressor miRNA to down-regulate the expression of some oncogenes to improve prognosis for ccRCC. On the other hand, up-regulated TFs could up-regulate miRNA expression to inhibit the expression of some tumor suppressor genes, whilst the up-regulated miRNAs could also down-regulate the expression of some TFs to further down-regulate the expression of some miRNAs to up-regulate the expression of some tumor suppressor genes, which might promote ccRCC development. Taken together, our results seemed to reveal that the interplay between TFs and miRNAs might synergistically regulate the expression of a certain number of oncogenes, driver genes, and tumor suppressor genes to improve prognosis for ccRCC patients in transcriptional and post-transcriptional levels.</p></sec></sec><sec sec-type="discussion" id="sec3-cancers-11-01668"><title>3. Discussion</title><p>At present, a number of miRNAs have been suggested as diagnosic and prognosic biomarkers for ccRCC patients, but, since a single miRNA mainly fine-tunes gene expression to execute its function, and the functional effect of a single miRNA is relatively weak, which might result in a lack of miRNA application into the clinical diagnosis and prognosis for ccRCC patients. Many studies have shown that miRNAs are more likely to regulate a certain number of gene expressions to control cell fate [<xref rid="B52-cancers-11-01668" ref-type="bibr">52</xref>,<xref rid="B53-cancers-11-01668" ref-type="bibr">53</xref>]. Remarkably, several studies have revealed that TFs can regulate miRNA expressions, whilst miRNAs may also regulate TF expressions, and TFs and miRNAs interplay can precisely modulate gene expression in transcriptional and post-transcriptional levels [<xref rid="B36-cancers-11-01668" ref-type="bibr">36</xref>,<xref rid="B45-cancers-11-01668" ref-type="bibr">45</xref>,<xref rid="B54-cancers-11-01668" ref-type="bibr">54</xref>,<xref rid="B55-cancers-11-01668" ref-type="bibr">55</xref>,<xref rid="B56-cancers-11-01668" ref-type="bibr">56</xref>,<xref rid="B57-cancers-11-01668" ref-type="bibr">57</xref>]. However, the regulatory landscape by miRNAs and TFs interplay is still largely unknown in the tumorigenesis and progression of ccRCC up to now. Especially, the interplay network of miRNA and TF has not yet been systemically studied in ccRCC. Therefore, in this current work, we have integratedly analyzed miRNA, TF, and mRNA profilings, and identified some potential diagnostic and prognostic factors participated in the survival of ccRCC patients, as well as revealed a possible molecular mechanism that miRNA and TF interplay can serve as an effective prognostic factor to facilitate the survival of ccRCC patients. </p><p>In this study, we have identified eight potentially diagnostic and prognostic miRNAs that could significantly distinguish the survival and pathological stratification for ccRCC patients. Among them, four down-regulated miRNAs (hsa-miR-9-5p, hsa-miR-1269a, hsa-miR-183-5p, hsa-miR-335-3p) could serve as good prognostic factors for clinical application of ccRCC patients, conversely the three up-regulated hsa-miR-365b-3p, hsa-miR-223-3p and hsa-miR-3613-5p of them might been acted as poor prognostic factors for ccRCC patients (<xref ref-type="fig" rid="cancers-11-01668-f002">Figure 2</xref>). At present, a few studies have reported that hsa-miR-183-5p can promote canceration by targeting SRSF2 in renal cancer [<xref rid="B58-cancers-11-01668" ref-type="bibr">58</xref>], miR-335 could inhibit the proliferation and invasion of clear renal cells through suppressing Bcl-w [<xref rid="B59-cancers-11-01668" ref-type="bibr">59</xref>], hsa-miR-365b-3p is poorly associated with ccRCC patient survival [<xref rid="B60-cancers-11-01668" ref-type="bibr">60</xref>] and hsa-miR-9-5p is associated with the development and risk of renal cancer recurrence [<xref rid="B61-cancers-11-01668" ref-type="bibr">61</xref>]. Although studies on the function roles of the other three miRNAs in ccRCC are still less reported to date, some other studies have revealed that hsa-miR-1269a could function as an onco-miRNA in NSCLC via down-regulating its target SOX6 [<xref rid="B62-cancers-11-01668" ref-type="bibr">62</xref>], as well as that miR-1269a could promote colorectal cancer (CRC) metastasis by targeting Smad7 and HOXD10 [<xref rid="B63-cancers-11-01668" ref-type="bibr">63</xref>]. The highly expressed hsa-miR-3613 as a oncogene could inhibit apoptosis via the down-regulation of target <italic>APAF1</italic> in human neuroblastoma BE(2)-C cells, as well as serve as a potential prognostic biomarker for pancreatic adenocarcinoma [<xref rid="B64-cancers-11-01668" ref-type="bibr">64</xref>]. Some recent studies have indicated that miR-223-3p could down-regulate aNHEJ expression to result in synthetic lethality in human BRCA1-deficient cancers [<xref rid="B65-cancers-11-01668" ref-type="bibr">65</xref>], and also act as an oncogenic miRNA in colon cancer through regulating EMT and PRDM1 [<xref rid="B66-cancers-11-01668" ref-type="bibr">66</xref>]. These previous studies have revealed that the high expression of the seven miRNAs could down-regulate the respective tumor suppressor genes or driver genes involved in different malignant tumor occurrences. Especially, the same miRNA might regulate different target genes involved in specific tumor formation, which suggests that the different roles of same miRNA might depend on different cell microenvironment and cancer types. Interestingly, our present study has indicated that the seven aforementioned miRNAs mainly regulate tumor suppressor and/or driver genes to involve in ccRCC. Thus, we suggest that the seven miRNAs could served as potentially diagnostic and prognostic factors that may be due to the four down-regulated miRNAs that could restore or elevate the expression level of a certain number of tumor suppressor or driver genes to improve the survival of ccRCC patients, whereas the three up-regulated miRNAs might decrease the expression level of many tumor suppressor genes to result in the worse survival of ccRCC patients. Particularly, our present findings have shown that the highly expressed hsa-miR-144-5p could reduce the expression level of multiple oncogenic genes to promote the survival for ccRCC prognosis. A previous study has also shown that the hsa-miR-144-5p could serve as a tumor-suppressor gene for inhibiting cell growth and arresting cells in the G1 phase in renal cancer [<xref rid="B30-cancers-11-01668" ref-type="bibr">30</xref>], which is also agreement with our present result. Taken together, we urge that hsa-miR-223-3p, hsa-miR-365b-3p, hsa-miR-3613-5p, hsa-miR-9-5p, hsa-miR-183-5p, hsa-miR-335-3p, and hsa-miR-1269a could serve as oncogenic miRNAs, as well as the hsa-miR-144-5p could act as a tumor suppressor miRNA for ccRCC patient diagnosis, but it is still further experimental verification.</p><p>A single miRNA molecule is known to carry out its function through fine-tuning the expression of target genes [<xref rid="B42-cancers-11-01668" ref-type="bibr">42</xref>,<xref rid="B43-cancers-11-01668" ref-type="bibr">43</xref>]. Therefore, it is hard to say that the expression of a single gene regulated by a single miRNA could significantly impact the proliferation and migration of cancer cell. Here, our findings seem to imply that single miRNA might need to regulate the expression of a lot of genes involved in the progression of ccRCC, suggesting that a single miRNA might be more suitable for ccRCC diagnosis and prognosis than a single gene. Specially, multiple miRNAs prefer synergistically or antagonistically regulating one or more target genes to control the strength and duration of cell response [<xref rid="B42-cancers-11-01668" ref-type="bibr">42</xref>,<xref rid="B43-cancers-11-01668" ref-type="bibr">43</xref>]. Thus, the combined multi-miRNAs as diagnosic and prognosic factors might be more suitable for the clinical application of ccRCC patients than a single miRNA. In the present study, just as we wish the prognostic effect and the credibility of the eight-miRNA signature are clearly superior to a single miRNA (<xref ref-type="fig" rid="cancers-11-01668-f003">Figure 3</xref>, <xref ref-type="app" rid="app1-cancers-11-01668">Figure S3 and Table S4</xref>), implying that the cooperative regulation of multi-miRNAs might play very important roles in tumorigenesis and progression of ccRCC. </p><p>In the present work, we have found that eight prognostic miRNAs could interplay with twenty-two TFs. Many studies have revealed that the interplay between miRNA and TFs play key roles in establishing and maintaining cell phenotype [<xref rid="B67-cancers-11-01668" ref-type="bibr">67</xref>,<xref rid="B68-cancers-11-01668" ref-type="bibr">68</xref>,<xref rid="B69-cancers-11-01668" ref-type="bibr">69</xref>]. Notably, in the gene regulatory network, TF and miRNA interplay could constitute positive or negative feedback loops to execute similar and opposing functions, which can precisely control the regulation of gene expression to reduce noise and maintain cell homeostasis [<xref rid="B40-cancers-11-01668" ref-type="bibr">40</xref>,<xref rid="B70-cancers-11-01668" ref-type="bibr">70</xref>,<xref rid="B71-cancers-11-01668" ref-type="bibr">71</xref>]. Therefore, while considering the complexity of TFs and miRNAs interplay regulating gene expression, we further constructed an interplay network of TF-miRNA and propose a potential molecular mechanism that the interaction between TFs and miRNAs facilitates the survival of ccRCC patients (<xref ref-type="fig" rid="cancers-11-01668-f010">Figure 10</xref>). As shown in <xref ref-type="fig" rid="cancers-11-01668-f010">Figure 10</xref>, down-regulated transcription factors, such as KLF5 and GATA2, can down-regulate miR-183-3p and miR-1269a to up-regulated FAS and other tumor suppressor genes, whilst down-regulated miR-183-3p and miR-1269a can also up-regulate IKZF1 and IRF1 to down-regulated downstream targets. Additionally, up-regulated MYC and IKZF1 can activate miR-223-3p and miR-365b-3p to down-regulate RPS6KA6, DEPTOR, and other tumor suppressor genes, whilst miR-223-3p and miR-365b-3p can also down-regulate TFAP2A and GATA2 to down-regulate miR-183-5p and miR-1269a to up-regulated FAS and VEGFA. Remarkably, some previous reports showed that the transcription factor GATA2 could activate the expression of miR-194 to promote this distant metastasis of prostate cancer by inhibiting SOCS2 [<xref rid="B72-cancers-11-01668" ref-type="bibr">72</xref>], and the transcription factor KLF5 could also promote the expression of miR-145, miR-124, and miR-183 by binding to their promoter involved in the progression of invasive pituitary adenoma [<xref rid="B73-cancers-11-01668" ref-type="bibr">73</xref>], as well as the transcription factor TFAP2C could promote lung tumorigenesis and aggressiveness through it activating miR-183 and miR-33a-mediated cell cycle regulation [<xref rid="B74-cancers-11-01668" ref-type="bibr">74</xref>]. Especially, the interplay of MYC and hsa-miR-144 has been reported in chronic myelogenous leukemia cell K562 [<xref rid="B75-cancers-11-01668" ref-type="bibr">75</xref>], and the transcription factor E2F1 could also up-regulate miR-224/452 expressions to inhibit the expression of TXNIP to drive EMT in malignant melanoma [<xref rid="B36-cancers-11-01668" ref-type="bibr">36</xref>], as well as miR-3188, as a tumour suppressor, could control the nasopharyngeal carcinoma proliferation and chemosensitivity through a mechanism where FOXO1 modulated a positive feedback loop of mTOR-p-PI3K/AKT-c-JUN [<xref rid="B38-cancers-11-01668" ref-type="bibr">38</xref>]. These above results supported our conclusion that the interplays between transcription factors and miRNAs might play very important roles in the prognosis of ccRCC patients. Thus, based on the importance of TF and miRNA interplay in gene expression regulation, we ultimately screened six miRNAs (hsa-miR-365b-3p, hsa-miR-223-3p, hsa-miR-1269a, hsa-miR-144-5p, hsa-miR-183-5p, hsa-miR-335-3p) and five TFs (TFAP2A, KLF5, IRF1, MYC, IKZF1) as an integrative prognostic predictor. Interestingly, the prognostic effect and the credibility of the combined six miRNAs and five TFs signature are better than both the eight-miRNA signature and the nine-TF signature. The reason might be that not only TFs can regulate the expression of multiple target genes, including miRNAs, but also miRNAs can fine-tune multiple gene expressions, including TFs, as well as their closely coordinated regulations control cell homeostasis. This also suggests why TFs and miRNAs interplay is effective as a clinical prognostic factor for ccRCC patients. Of course, all of these regulatory pairs predicted by bioinformatics and data integration are still to be further verified experimentally. </p></sec><sec id="sec4-cancers-11-01668"><title>4. Materials and Method</title><sec id="sec4dot1-cancers-11-01668"><title>4.1. Data Sources and Pre-Processing</title><p>All KIRC sample RNA-seq data of mRNA and miRNA isoform and corresponding clinical information were downloaded from the The Cancer Genome Atlas (TCGA) database (<uri xlink:href="https://portal.gdc.cancer.gov/">https://portal.gdc.cancer.gov/</uri>, Springer Netherlands, Bethesda, MD, USA). The samples were filtered based on survival days greater than three months and simultaneous possessing mRNA and miRNA expression data. Based on the AnimalTFDB3.0 (<uri xlink:href="http://bioinfo.life.hust.edu.cn/AnimalTFDB/">http://bioinfo.life.hust.edu.cn/AnimalTFDB/</uri>, Oxford University Press, Hubei, China.) and Ensemble (<uri xlink:href="http://asia.ensembl.org/index.html">http://asia.ensembl.org/index.html</uri>, Oxford University Press, Cambridgeshire, UK.) annotations, we identified 19,780 coding genes, of which 1400 were transcription factors. The expression level of 2,104 miRNA matures was obtained after miRNA isoform alignment. These lower expressed genes (sum(cpm) &#x0003c; 1) were removed and these genes expressed in at least 50% of the sample were retained.</p></sec><sec id="sec4dot2-cancers-11-01668"><title>4.2. Differentially Expressed Gene Analysis</title><p>Difference gene expression analysis between all tumor and paracancerous tissues was performed while using the edgeR package with filter parameters |log2FC| &#x0003e; 1 and <italic>p</italic>.adjust &#x0003c; 0.05. Similarly, differentially expressed miRNA was screened by limma package with criteria: |log2FC| &#x0003e; 1, <italic>p</italic>.adjust &#x0003c; 0.05. In addition, the mRNA and miRNA expression profiles were further respectively converted to log2 (normalized value + 1) and log2 (RPKM + 1) to be used for the next operation.</p></sec><sec id="sec4dot3-cancers-11-01668"><title>4.3. Survival Analysis and Prognosis Model Establishment</title><p>The samples of ccRCC with OS &#x0003e; 90 days were selected for survival analysis. Firstly, according to the median expression of miRNAs, batch survival analysis was performed to screen out the significantly differentially expressed miRNAs that are associated with survival. Subsequently, the univariate Cox regression was used to further assess the miRNAs related to survival. Only those miRNAs with a <italic>p</italic>-value &#x0003c; 0.001 were selected as candidate biomarker miRNAs. Finally, these candidate miRNAs were subjected to multivariate cox regression to determine independent prognostic marker miRNAs and calculate the risk value constructing prediction model for each miRNA. Based on the above results, the time-dependent receiver operating characteristic (ROC) curve was drawn using the Survival ROC R package, and the classification model was evaluated according to the area under the curve (AUC). In addition, we also analyzed the concordance index (C-index) and the Akaike information criterion (AIC). The C-index represents the consistency of the probability of the actual occurrence of the outcome and the probability of the prediction, and the AIC represents a standard for measuring the goodness of statistical model fitting. The prognostic signature of individual calculated according to the risk values of each marker miRNA and combined miRNAs. Next, the patient were divided into high and low risk groups according to the median risk score, and the survival analysis curve was then performed to check significant difference of patients in two groups over time.</p></sec><sec id="sec4dot4-cancers-11-01668"><title>4.4. miRNA Target Prediction and Target Function Analysis</title><p>These target genes of prognostic miRNAs were predicted by integrating Mirwalk3.0 (<uri xlink:href="http://mirwalk.umm.uni-heidelberg.de/">http://mirwalk.umm.uni-heidelberg.de/</uri>, Public Library of Science, Mannheim, Germany.) and a negative correlation between miRNA and mRNA expression. The Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was performed using the clusterProfiler package [<xref rid="B76-cancers-11-01668" ref-type="bibr">76</xref>] with the filtration standard: <italic>p</italic>.adjust &#x0003c; 0.05. The PPI network from target genes was derived from the STING database (<uri xlink:href="https://string-db.org/">https://string-db.org/</uri>, Oxford University Press, Zurich, Switzerland).</p></sec><sec id="sec4dot5-cancers-11-01668"><title>4.5. Prediction of Transcription Factors Regulating miRNAs</title><p>The TransmiR2.0 (<uri xlink:href="http://www.cuilab.cn/transmir">http://www.cuilab.cn/transmir</uri>, Oxford University Press, Beijing, China.) has collected the human regulatory pair of TFs regulating miRNAs (TFs-miRNAs) based on accurate transcriptional start site (TSS) of miRNA and ChIP-seq sequencing as well as experimental validation. Combining the TFs-miRNAs regulatory pair with the expression positive correlation of miRNAs and TFs, and TFs that may regulate these biomarker miRNAs were screened.</p></sec><sec id="sec4dot6-cancers-11-01668"><title>4.6. Data Statistics and Visualization</title><p>All data analysis was performed using R software (version 3.5.1, R Core Team, Vienna, Austria). Cytoscape software [<xref rid="B77-cancers-11-01668" ref-type="bibr">77</xref>] (version 3.6.1, Cold Spring Harbor Laboratory Press, Washington, WA, USA.) were used to visualize the network. The survival curve was plotted using Kaplan Meier function, and the difference significance was evaluated by log-rank test.</p></sec></sec><sec sec-type="conclusions" id="sec5-cancers-11-01668"><title>5. Conclusions</title><p>In this work, we have identified eight prognostic miRNAs. Among them, seven miRNAs (hsa-miR-223-3p, hsa-miR-365b-3p, hsa-miR-3613-5p hsa-miR-9-5p, hsa-miR-183-5p, hsa-miR-335-3p, hsa-miR-1269a) can serve as potential oncogenes, whereas hsa-miR-144-5p might act as a tumor suppressor gene for ccRCC diagnosis. In addition, the eleven-gene signature (hsa-miR-365b-3p, hsa-miR-223-3p, hsa-miR-1269a, hsa-miR-144-5p, hsa-miR-183-5p, hsa-miR-335-3p, <italic>TFAP2A</italic>, <italic>KLF5</italic>, <italic>IRF1</italic>, <italic>MYC</italic>, <italic>IKZF1</italic>) can sever as an effective prognostic predictor to significantly improve the overall survival of ccRCC patients. Especially, our study has revealed a possible molecular mechanism that TFs and miRNAs interplay can cooperatively regulate the expression of oncogenes, driver genes, and tumor suppressor genes to facilitate the survival of ccRCC patients. Thus, our findings not only provide a new insight into the mechanism that TFs and miRNAs interplay control the tumorigenesis and progression of ccRCC, but also identify several novel diagnostic and prognostic biomarkers as well as potential therapeutic targets that are very crucial for making individualized therapeutic strategies of ccRCC patients.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank our colleagues for their suggestions and criticisms on the manuscript.</p></ack><app-group><app id="app1-cancers-11-01668"><title>Supplementary Materials</title><p>The following are available online at <uri xlink:href="https://www.mdpi.com/2072-6694/11/11/1668/s1">https://www.mdpi.com/2072-6694/11/11/1668/s1</uri>, Figure S1: The volcano map of differentially expressed genes and miRNAs. The volcano map of differentially expressed miRNA (A) and mRNA (B). The red point represents up-regulated expression and the green point represents down-regulated expression with statistical significance (<italic>p</italic>-value &#x0003c; 0.05), Figure S2: Kaplan-Meier survival based on the risk score of eight miRNAs. Overall survival curves of high-risk and low-risk groups for hsa-miR-1269a (A), hsa-miR-183-5p (B), hsa-miR-9-5p (C), hsa-miR-335-3p (D), hsa-miR-3613-5p (E), hsa-miR-223-3p (F), hsa-miR-365b-3p (G), hsa-miR-144-5p (H), Figure S3: ROC curves based on the risk score of eight miRNAs. ROC curves for high and low risk of hsa-miR-1269a (A), hsa-miR-183-5p (B), hsa-miR-9-5p (C), hsa-miR-335-3p (D), hsa-miR-3613-5p (E), hsa-miR-223-3p (F), hsa-miR-365b-3p (G), hsa-miR-144-5p (H), Figure S4: The correlation between the expression level of eight prognostic miRNAs and clinical factors. The correlation heat map between clinical parameters and prognostic miRNA expression levels in ccRCC. The red box represents a <italic>p</italic>-value &#x0003c; 0.05; the green box represents a <italic>p</italic>-value &#x0003e; 0.05, Figure S5: The KEGG signaling pathway analysis of up-regulated and down-regulated targets. Signaling pathways of KEGG enrichment of up-regulated targets(A) and down-regulated targets(B), Figure S6: Transcription factors regulating eight miRNAs. Six down-regulated transcription factors down-regulate three down-regulated miRNAs (A); sixteen up-regulate transcription factors up-regulate four up-regulated miRNAs (B). The red represents up-regulation of gene expression and the blue represents down-regulation of gene expression. Table S1: These 37 miRNAs are related to ccRCC survival, Table S2: These top 21 miRNAs are significant associated with ccRCC survival, Table S3: The correlation between prognostic miRNA expression levels and clinical factors, Table S4: The concordance index (C-index) and Akaike information criterion (AIC) of combined miRNAs and single miRNA model, Table S5: These top 30 hub genes from PPI network. Table S6: Targets of has-miR-144-5p. Table S7: TF-miRNA regulation pairs, Table S8. The C-index and AIC of TFs and miRNAs.</p><supplementary-material content-type="local-data" id="cancers-11-01668-s001"><media xlink:href="cancers-11-01668-s001.zip"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>F.M. and P.J. designed this study and edited this manuscript; S.Q. and X.S. acquired and analyzed the data; S.Q. and P.J. wrote the original draft; P.J. supervised this project; C.W. collected literatures. All authors read and approved the manuscript.</p></notes><notes><title>Funding</title><p>This research was funded by grants from the National Natural Science Foundation of China (No. 31970477) and the Natural Science Foundation of Jiangsu Province (No. BK20191368).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-cancers-11-01668"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choudhary</surname><given-names>S.</given-names></name><name><surname>Sudarshan</surname><given-names>S.</given-names></name><name><surname>Choyke</surname><given-names>P.L.</given-names></name><name><surname>Prasad</surname><given-names>S.R.</given-names></name></person-group><article-title>Renal cell carcinoma: Recent advances in genetics and imaging</article-title><source>Semin. Ultrasound CT MR</source><year>2009</year><volume>30</volume><fpage>315</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1053/j.sult.2009.03.003</pub-id><?supplied-pmid 19711643?><pub-id pub-id-type="pmid">19711643</pub-id></element-citation></ref><ref id="B2-cancers-11-01668"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R.L.</given-names></name><name><surname>Miller</surname><given-names>K.D.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Cancer statistics, 2018</article-title><source>CA A Cancer J. Clin.</source><year>2018</year><volume>68</volume><fpage>7</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.3322/caac.21442</pub-id><?supplied-pmid 29313949?><pub-id pub-id-type="pmid">29313949</pub-id></element-citation></ref><ref id="B3-cancers-11-01668"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellido</surname><given-names>J.A.</given-names></name><name><surname>Palou</surname><given-names>J.</given-names></name><name><surname>Hubner</surname><given-names>M.</given-names></name><name><surname>Pascual</surname><given-names>M.</given-names></name><name><surname>Sagrista</surname><given-names>R.</given-names></name><name><surname>Martinez</surname><given-names>E.</given-names></name><name><surname>Martinez</surname><given-names>J.</given-names></name><name><surname>Rosales</surname><given-names>A.</given-names></name><name><surname>Villavicencio</surname><given-names>H.</given-names></name></person-group><article-title>[Early ultrasound detection of renal tumors in patients with end stage renal disease in dialysis]</article-title><source>Arch. Esp. Urol.</source><year>2007</year><volume>60</volume><fpage>079</fpage><lpage>083</lpage><?supplied-pmid 18077861?><pub-id pub-id-type="pmid">18077861</pub-id></element-citation></ref><ref id="B4-cancers-11-01668"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrera-Carrillo</surname><given-names>E.</given-names></name><name><surname>Berkhout</surname><given-names>B.</given-names></name></person-group><article-title>Dicer-independent processing of small RNA duplexes: Mechanistic insights and applications</article-title><source>Nucleic Acids Res.</source><year>2017</year><volume>45</volume><fpage>10369</fpage><lpage>10379</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx779</pub-id><?supplied-pmid 28977573?><pub-id pub-id-type="pmid">28977573</pub-id></element-citation></ref><ref id="B5-cancers-11-01668"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>R.C.</given-names></name><name><surname>Ambros</surname><given-names>V.</given-names></name></person-group><article-title>An extensive class of small RNAs in Caenorhabditis elegans</article-title><source>Science</source><year>2001</year><volume>294</volume><fpage>862</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.1126/science.1065329</pub-id><?supplied-pmid 11679672?><pub-id pub-id-type="pmid">11679672</pub-id></element-citation></ref><ref id="B6-cancers-11-01668"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>T.B.</given-names></name></person-group><article-title>Detecting Agotrons in Ago CLIPseq Data</article-title><source>Methods Mol. Biol.</source><year>2018</year><volume>1823</volume><fpage>221</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-8624-8_17</pub-id><?supplied-pmid 29959685?><pub-id pub-id-type="pmid">29959685</pub-id></element-citation></ref><ref id="B7-cancers-11-01668"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartel</surname><given-names>D.P.</given-names></name></person-group><article-title>MicroRNAs: Target recognition and regulatory functions</article-title><source>Cell</source><year>2009</year><volume>136</volume><fpage>215</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.01.002</pub-id><pub-id pub-id-type="pmid">19167326</pub-id></element-citation></ref><ref id="B8-cancers-11-01668"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>W.C.</given-names></name></person-group><article-title>OncomiRs: The discovery and progress of microRNAs in cancers</article-title><source>Mol. Cancer</source><year>2007</year><volume>6</volume><fpage>60</fpage><pub-id pub-id-type="doi">10.1186/1476-4598-6-60</pub-id><pub-id pub-id-type="pmid">17894887</pub-id></element-citation></ref><ref id="B9-cancers-11-01668"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>N.</given-names></name><name><surname>Ekanem</surname><given-names>N.R.</given-names></name><name><surname>Sakyi</surname><given-names>C.A.</given-names></name><name><surname>Ray</surname><given-names>S.D.</given-names></name></person-group><article-title>Hepatocellular carcinoma and microRNA: New perspectives on therapeutics and diagnostics</article-title><source>Adv. Drug Deliv. Rev.</source><year>2015</year><volume>81</volume><fpage>62</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2014.10.029</pub-id><pub-id pub-id-type="pmid">25450260</pub-id></element-citation></ref><ref id="B10-cancers-11-01668"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klingenberg</surname><given-names>M.</given-names></name><name><surname>Matsuda</surname><given-names>A.</given-names></name><name><surname>Diederichs</surname><given-names>S.</given-names></name><name><surname>Patel</surname><given-names>T.</given-names></name></person-group><article-title>Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets</article-title><source>J. Hepatol.</source><year>2017</year><volume>67</volume><fpage>603</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2017.04.009</pub-id><pub-id pub-id-type="pmid">28438689</pub-id></element-citation></ref><ref id="B11-cancers-11-01668"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>W.L.</given-names></name><name><surname>Wang</surname><given-names>W.Y.</given-names></name><name><surname>Yao</surname><given-names>W.Q.</given-names></name><name><surname>Li</surname><given-names>G.D.</given-names></name></person-group><article-title>Suppressive effects of microRNA-16 on the proliferation, invasion and metastasis of hepatocellular carcinoma cells</article-title><source>Int. J. Mol. Med.</source><year>2015</year><volume>36</volume><fpage>1713</fpage><lpage>1719</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2015.2379</pub-id><?supplied-pmid 26499886?><pub-id pub-id-type="pmid">26499886</pub-id></element-citation></ref><ref id="B12-cancers-11-01668"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>F.</given-names></name><name><surname>Henson</surname><given-names>R.</given-names></name><name><surname>Wehbe-Janek</surname><given-names>H.</given-names></name><name><surname>Ghoshal</surname><given-names>K.</given-names></name><name><surname>Jacob</surname><given-names>S.T.</given-names></name><name><surname>Patel</surname><given-names>T.</given-names></name></person-group><article-title>MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer</article-title><source>Gastroenterology</source><year>2007</year><volume>133</volume><fpage>647</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2007.05.022</pub-id><?supplied-pmid 17681183?><pub-id pub-id-type="pmid">17681183</pub-id></element-citation></ref><ref id="B13-cancers-11-01668"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>C.C.</given-names></name><name><surname>Wong</surname><given-names>C.M.</given-names></name><name><surname>Tung</surname><given-names>E.K.</given-names></name><name><surname>Au</surname><given-names>S.L.</given-names></name><name><surname>Lee</surname><given-names>J.M.</given-names></name><name><surname>Poon</surname><given-names>R.T.</given-names></name><name><surname>Man</surname><given-names>K.</given-names></name><name><surname>Ng</surname><given-names>I.O.</given-names></name></person-group><article-title>The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2</article-title><source>Gastroenterology</source><year>2011</year><volume>140</volume><fpage>322</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2010.10.006</pub-id><?supplied-pmid 20951699?><pub-id pub-id-type="pmid">20951699</pub-id></element-citation></ref><ref id="B14-cancers-11-01668"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>F.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>Shan</surname><given-names>J.</given-names></name><name><surname>Shen</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Cui</surname><given-names>Y.</given-names></name><name><surname>Bian</surname><given-names>X.</given-names></name><name><surname>Bie</surname><given-names>P.</given-names></name><etal/></person-group><article-title>MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest</article-title><source>Cancer Lett.</source><year>2011</year><volume>310</volume><fpage>160</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2011.06.027</pub-id><pub-id pub-id-type="pmid">21802841</pub-id></element-citation></ref><ref id="B15-cancers-11-01668"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Kong</surname><given-names>W.</given-names></name><name><surname>Gong</surname><given-names>D.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Xue</surname><given-names>W.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name></person-group><article-title>Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals</article-title><source>Mol. Cancer</source><year>2018</year><volume>17</volume><fpage>157</fpage><pub-id pub-id-type="doi">10.1186/s12943-018-0906-x</pub-id><pub-id pub-id-type="pmid">30419914</pub-id></element-citation></ref><ref id="B16-cancers-11-01668"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>P.J.</given-names></name></person-group><article-title>MicroRNAs as promising biomarkers in cancer diagnostics</article-title><source>Biomark. Res.</source><year>2014</year><volume>2</volume><fpage>19</fpage><pub-id pub-id-type="doi">10.1186/2050-7771-2-19</pub-id><pub-id pub-id-type="pmid">25356314</pub-id></element-citation></ref><ref id="B17-cancers-11-01668"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>X.F.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Jia</surname><given-names>H.L.</given-names></name><name><surname>Liang</surname><given-names>L.</given-names></name><name><surname>Dong</surname><given-names>Q.Z.</given-names></name><name><surname>Ye</surname><given-names>Q.H.</given-names></name><name><surname>Qin</surname><given-names>L.X.</given-names></name></person-group><article-title>MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway</article-title><source>Hepatology</source><year>2014</year><volume>59</volume><fpage>1874</fpage><lpage>1885</lpage><pub-id pub-id-type="doi">10.1002/hep.26941</pub-id><pub-id pub-id-type="pmid">24259426</pub-id></element-citation></ref><ref id="B18-cancers-11-01668"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>Q.J.</given-names></name><name><surname>Gong</surname><given-names>Z.B.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>You</surname><given-names>N.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>X.L.</given-names></name><name><surname>Li</surname><given-names>J.J.</given-names></name><name><surname>An</surname><given-names>J.Z.</given-names></name><name><surname>Wang</surname><given-names>D.S.</given-names></name><etal/></person-group><article-title>MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment</article-title><source>Technol. Cancer Res. Treat.</source><year>2014</year><volume>13</volume><fpage>77</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.7785/tcrt.2012.500364</pub-id><pub-id pub-id-type="pmid">23862748</pub-id></element-citation></ref><ref id="B19-cancers-11-01668"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hua</surname><given-names>S.</given-names></name><name><surname>Lei</surname><given-names>L.</given-names></name><name><surname>Deng</surname><given-names>L.</given-names></name><name><surname>Weng</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Qi</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Zou</surname><given-names>X.</given-names></name><name><surname>Cao</surname><given-names>C.</given-names></name><etal/></person-group><article-title>miR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with ETS1</article-title><source>Oncogene</source><year>2018</year><volume>37</volume><fpage>1624</fpage><lpage>1636</lpage><pub-id pub-id-type="doi">10.1038/s41388-017-0057-3</pub-id><pub-id pub-id-type="pmid">29335523</pub-id></element-citation></ref><ref id="B20-cancers-11-01668"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youssef</surname><given-names>Y.M.</given-names></name><name><surname>White</surname><given-names>N.M.</given-names></name><name><surname>Grigull</surname><given-names>J.</given-names></name><name><surname>Krizova</surname><given-names>A.</given-names></name><name><surname>Samy</surname><given-names>C.</given-names></name><name><surname>Mejia-Guerrero</surname><given-names>S.</given-names></name><name><surname>Evans</surname><given-names>A.</given-names></name><name><surname>Yousef</surname><given-names>G.M.</given-names></name></person-group><article-title>Accurate molecular classification of kidney cancer subtypes using microRNA signature</article-title><source>Eur. Urol.</source><year>2011</year><volume>59</volume><fpage>721</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2011.01.004</pub-id><pub-id pub-id-type="pmid">21272993</pub-id></element-citation></ref><ref id="B21-cancers-11-01668"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braga</surname><given-names>E.A.</given-names></name><name><surname>Fridman</surname><given-names>M.V.</given-names></name><name><surname>Loginov</surname><given-names>V.I.</given-names></name><name><surname>Dmitriev</surname><given-names>A.A.</given-names></name><name><surname>Morozov</surname><given-names>S.G.</given-names></name></person-group><article-title>Molecular Mechanisms in Clear Cell Renal Cell Carcinoma: Role of miRNAs and Hypermethylated miRNA Genes in Crucial Oncogenic Pathways and Processes</article-title><source>Front. Genet.</source><year>2019</year><volume>10</volume><fpage>320</fpage><pub-id pub-id-type="doi">10.3389/fgene.2019.00320</pub-id><?supplied-pmid 31110513?><pub-id pub-id-type="pmid">31110513</pub-id></element-citation></ref><ref id="B22-cancers-11-01668"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Dai</surname><given-names>H.</given-names></name><name><surname>Walsh</surname><given-names>R.M.</given-names></name><name><surname>Imakura</surname><given-names>M.</given-names></name><name><surname>Schelter</surname><given-names>J.</given-names></name><name><surname>Burchard</surname><given-names>J.</given-names></name><name><surname>Dai</surname><given-names>X.</given-names></name><name><surname>Chang</surname><given-names>A.N.</given-names></name><name><surname>Diaz</surname><given-names>R.L.</given-names></name><etal/></person-group><article-title>MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT</article-title><source>Cell Cycle</source><year>2009</year><volume>8</volume><fpage>2756</fpage><lpage>2768</lpage><pub-id pub-id-type="doi">10.4161/cc.8.17.9387</pub-id><?supplied-pmid 19652553?><pub-id pub-id-type="pmid">19652553</pub-id></element-citation></ref><ref id="B23-cancers-11-01668"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Qi</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Miao</surname><given-names>X.</given-names></name><name><surname>Zheng</surname><given-names>W.</given-names></name><name><surname>Jia</surname><given-names>L.</given-names></name></person-group><article-title>MiR-193a-3p and miR-224 mediate renal cell carcinoma progression by targeting alpha-2,3-sialyltransferase IV and the phosphatidylinositol 3 kinase/Akt pathway</article-title><source>Mol. Carcinog.</source><year>2018</year><volume>57</volume><fpage>1067</fpage><lpage>1077</lpage><pub-id pub-id-type="doi">10.1002/mc.22826</pub-id><?supplied-pmid 29667779?><pub-id pub-id-type="pmid">29667779</pub-id></element-citation></ref><ref id="B24-cancers-11-01668"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fedorko</surname><given-names>M.</given-names></name><name><surname>Pacik</surname><given-names>D.</given-names></name><name><surname>Wasserbauer</surname><given-names>R.</given-names></name><name><surname>Juracek</surname><given-names>J.</given-names></name><name><surname>Varga</surname><given-names>G.</given-names></name><name><surname>Ghazal</surname><given-names>M.</given-names></name><name><surname>Nussir</surname><given-names>M.I.</given-names></name></person-group><article-title>MicroRNAs in the pathogenesis of renal cell carcinoma and their diagnostic and prognostic utility as cancer biomarkers</article-title><source>Int. J. Biol. Mark.</source><year>2016</year><volume>31</volume><fpage>e26</fpage><lpage>e37</lpage><pub-id pub-id-type="doi">10.5301/jbm.5000174</pub-id></element-citation></ref><ref id="B25-cancers-11-01668"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>R.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Zheng</surname><given-names>L.</given-names></name><name><surname>Xue</surname><given-names>Z.</given-names></name><name><surname>Xia</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><etal/></person-group><article-title>MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma</article-title><source>BMC Cancer</source><year>2012</year><volume>12</volume><elocation-id>546</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-12-546</pub-id><pub-id pub-id-type="pmid">23173671</pub-id></element-citation></ref><ref id="B26-cancers-11-01668"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>R.C.</given-names></name><name><surname>Ivanovic</surname><given-names>R.F.</given-names></name><name><surname>Leite</surname><given-names>K.R.M.</given-names></name><name><surname>Viana</surname><given-names>N.I.</given-names></name><name><surname>Pimenta</surname><given-names>R.C.A.</given-names></name><name><surname>Junior</surname><given-names>J.P.</given-names></name><name><surname>Guimaraes</surname><given-names>V.R.</given-names></name><name><surname>Morais</surname><given-names>D.R.</given-names></name><name><surname>Abe</surname><given-names>D.K.</given-names></name><name><surname>Nesrallah</surname><given-names>A.J.</given-names></name><etal/></person-group><article-title>Expression of micro-RNAs and genes related to angiogenesis in ccRCC and associations with tumor characteristics</article-title><source>BMC Urol.</source><year>2017</year><volume>17</volume><elocation-id>113</elocation-id><pub-id pub-id-type="doi">10.1186/s12894-017-0306-3</pub-id><pub-id pub-id-type="pmid">29202733</pub-id></element-citation></ref><ref id="B27-cancers-11-01668"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>W.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Tao</surname><given-names>D.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Luo</surname><given-names>G.</given-names></name><name><surname>Xiao</surname><given-names>X.</given-names></name><name><surname>Zeng</surname><given-names>F.</given-names></name><etal/></person-group><article-title>miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>4066</fpage><lpage>4079</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.2926</pub-id><pub-id pub-id-type="pmid">25714014</pub-id></element-citation></ref><ref id="B28-cancers-11-01668"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Y.J.</given-names></name><name><surname>Wei</surname><given-names>L.L.</given-names></name><name><surname>Wu</surname><given-names>X.J.</given-names></name><name><surname>Huo</surname><given-names>F.C.</given-names></name><name><surname>Mou</surname><given-names>J.</given-names></name><name><surname>Pei</surname><given-names>D.S.</given-names></name></person-group><article-title>MiR-106a-5p inhibits the cell migration and invasion of renal cell carcinoma through targeting PAK5</article-title><source>Cell Death Dis.</source><year>2017</year><volume>8</volume><fpage>e3155</fpage><pub-id pub-id-type="doi">10.1038/cddis.2017.561</pub-id><pub-id pub-id-type="pmid">29072688</pub-id></element-citation></ref><ref id="B29-cancers-11-01668"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>T.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Gui</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Lai</surname><given-names>Y.</given-names></name></person-group><article-title>miR-125b is associated with renal cell carcinoma cell migration, invasion and apoptosis</article-title><source>Oncol. Lett.</source><year>2017</year><volume>13</volume><fpage>4512</fpage><lpage>4520</lpage><pub-id pub-id-type="doi">10.3892/ol.2017.5985</pub-id><pub-id pub-id-type="pmid">28599452</pub-id></element-citation></ref><ref id="B30-cancers-11-01668"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>C.</given-names></name><name><surname>Cui</surname><given-names>S.P.</given-names></name><name><surname>Ke</surname><given-names>Y.</given-names></name></person-group><article-title>MiR-144 inhibits cell proliferation of renal cell carcinoma by targeting MTOR</article-title><source>J. Huazhong Univ. Sci. Technol. Med. Sci. = Hua zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban</source><year>2016</year><volume>36</volume><fpage>186</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1007/s11596-016-1564-0</pub-id><pub-id pub-id-type="pmid">27072960</pub-id></element-citation></ref><ref id="B31-cancers-11-01668"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>W.</given-names></name><name><surname>Lou</surname><given-names>N.</given-names></name><name><surname>Ruan</surname><given-names>H.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Xiong</surname><given-names>Z.</given-names></name><name><surname>Yuan</surname><given-names>C.</given-names></name><name><surname>Tong</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>G.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Qu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A</article-title><source>Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol.</source><year>2017</year><volume>43</volume><fpage>2420</fpage><lpage>2433</lpage><pub-id pub-id-type="doi">10.1159/000484395</pub-id></element-citation></ref><ref id="B32-cancers-11-01668"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Gu</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Da</surname><given-names>J.</given-names></name></person-group><article-title>miR-203 inhibition of renal cancer cell proliferation, migration and invasion by targeting of FGF2</article-title><source>Diagn. Pathol.</source><year>2015</year><volume>10</volume><fpage>24</fpage><pub-id pub-id-type="doi">10.1186/s13000-015-0255-7</pub-id><?supplied-pmid 25890121?><pub-id pub-id-type="pmid">25890121</pub-id></element-citation></ref><ref id="B33-cancers-11-01668"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>G.</given-names></name><name><surname>Lai</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Guo</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Yao</surname><given-names>X.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><etal/></person-group><article-title>miR-203a regulates proliferation, migration, and apoptosis by targeting glycogen synthase kinase-3beta in human renal cell carcinoma</article-title><source>Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med.</source><year>2014</year><volume>35</volume><fpage>11443</fpage><lpage>11453</lpage><pub-id pub-id-type="doi">10.1007/s13277-014-2476-x</pub-id><?supplied-pmid 25123268?><pub-id pub-id-type="pmid">25123268</pub-id></element-citation></ref><ref id="B34-cancers-11-01668"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fedorko</surname><given-names>M.</given-names></name><name><surname>Stanik</surname><given-names>M.</given-names></name><name><surname>Iliev</surname><given-names>R.</given-names></name><name><surname>Redova-Lojova</surname><given-names>M.</given-names></name><name><surname>Machackova</surname><given-names>T.</given-names></name><name><surname>Svoboda</surname><given-names>M.</given-names></name><name><surname>Pacik</surname><given-names>D.</given-names></name><name><surname>Dolezel</surname><given-names>J.</given-names></name><name><surname>Slaby</surname><given-names>O.</given-names></name></person-group><article-title>Combination of MiR-378 and MiR-210 Serum Levels Enables Sensitive Detection of Renal Cell Carcinoma</article-title><source>Int. J. Mol. Sci.</source><year>2015</year><volume>16</volume><fpage>23382</fpage><lpage>23389</lpage><pub-id pub-id-type="doi">10.3390/ijms161023382</pub-id><?supplied-pmid 26426010?><pub-id pub-id-type="pmid">26426010</pub-id></element-citation></ref><ref id="B35-cancers-11-01668"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redova</surname><given-names>M.</given-names></name><name><surname>Poprach</surname><given-names>A.</given-names></name><name><surname>Nekvindova</surname><given-names>J.</given-names></name><name><surname>Iliev</surname><given-names>R.</given-names></name><name><surname>Radova</surname><given-names>L.</given-names></name><name><surname>Lakomy</surname><given-names>R.</given-names></name><name><surname>Svoboda</surname><given-names>M.</given-names></name><name><surname>Vyzula</surname><given-names>R.</given-names></name><name><surname>Slaby</surname><given-names>O.</given-names></name></person-group><article-title>Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma</article-title><source>J. Transl. Med.</source><year>2012</year><volume>10</volume><fpage>55</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-10-55</pub-id><pub-id pub-id-type="pmid">22440013</pub-id></element-citation></ref><ref id="B36-cancers-11-01668"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knoll</surname><given-names>S.</given-names></name><name><surname>Furst</surname><given-names>K.</given-names></name><name><surname>Kowtharapu</surname><given-names>B.</given-names></name><name><surname>Schmitz</surname><given-names>U.</given-names></name><name><surname>Marquardt</surname><given-names>S.</given-names></name><name><surname>Wolkenhauer</surname><given-names>O.</given-names></name><name><surname>Martin</surname><given-names>H.</given-names></name><name><surname>Putzer</surname><given-names>B.M.</given-names></name></person-group><article-title>E2F1 induces miR-224/452 expression to drive EMT through TXNIP downregulation</article-title><source>EMBO Rep.</source><year>2014</year><volume>15</volume><fpage>1315</fpage><lpage>1329</lpage><pub-id pub-id-type="doi">10.15252/embr.201439392</pub-id><pub-id pub-id-type="pmid">25341426</pub-id></element-citation></ref><ref id="B37-cancers-11-01668"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name></person-group><article-title>Interplay of miR-21 and FoxO1 modulates growth of pancreatic ductal adenocarcinoma</article-title><source>Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med.</source><year>2015</year><volume>36</volume><fpage>4741</fpage><lpage>4745</lpage><pub-id pub-id-type="doi">10.1007/s13277-015-3123-x</pub-id></element-citation></ref><ref id="B38-cancers-11-01668"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Luo</surname><given-names>R.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>L.</given-names></name><name><surname>Fu</surname><given-names>Z.</given-names></name><name><surname>Fu</surname><given-names>Q.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>X.</given-names></name><name><surname>Liang</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>11309</fpage><pub-id pub-id-type="doi">10.1038/ncomms11309</pub-id><pub-id pub-id-type="pmid">27095304</pub-id></element-citation></ref><ref id="B39-cancers-11-01668"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>K.C.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Subramaniam</surname><given-names>S.</given-names></name><name><surname>Shyy</surname><given-names>J.Y.</given-names></name><name><surname>Chiu</surname><given-names>J.J.</given-names></name><name><surname>Li</surname><given-names>J.Y.</given-names></name><name><surname>Chien</surname><given-names>S.</given-names></name></person-group><article-title>MicroRNA-21 targets peroxisome proliferators-activated receptor-alpha in an autoregulatory loop to modulate flow-induced endothelial inflammation</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>10355</fpage><lpage>10360</lpage><pub-id pub-id-type="doi">10.1073/pnas.1107052108</pub-id><pub-id pub-id-type="pmid">21636785</pub-id></element-citation></ref><ref id="B40-cancers-11-01668"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Du</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Ecological Balance of Oral Microbiota Is Required to Maintain Oral Mesenchymal Stem Cell Homeostasis</article-title><source>Stem Cells</source><year>2018</year><volume>36</volume><fpage>551</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1002/stem.2762</pub-id><pub-id pub-id-type="pmid">29266799</pub-id></element-citation></ref><ref id="B41-cancers-11-01668"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shan</surname><given-names>J.</given-names></name><name><surname>Feng</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>P.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Interplay between mTOR and STAT5 signaling modulates the balance between regulatory and effective T cells</article-title><source>Immunobiology</source><year>2015</year><volume>220</volume><fpage>510</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2014.10.020</pub-id><pub-id pub-id-type="pmid">25468562</pub-id></element-citation></ref><ref id="B42-cancers-11-01668"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>S.</given-names></name><name><surname>Ma</surname><given-names>F.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name></person-group><article-title>Gene regulatory networks by transcription factors and microRNAs in breast cancer</article-title><source>Bioinformatics</source><year>2015</year><volume>31</volume><fpage>76</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu597</pub-id><pub-id pub-id-type="pmid">25189779</pub-id></element-citation></ref><ref id="B43-cancers-11-01668"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>W.L.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Story</surname><given-names>M.</given-names></name><name><surname>Shay</surname><given-names>J.W.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Amin</surname><given-names>A.R.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><etal/></person-group><article-title>OCT4 as a target of miR-34a stimulates p63 but inhibits p53 to promote human cell transformation</article-title><source>Cell Death Dis.</source><year>2014</year><volume>5</volume><fpage>e1024</fpage><pub-id pub-id-type="doi">10.1038/cddis.2013.563</pub-id><pub-id pub-id-type="pmid">24457968</pub-id></element-citation></ref><ref id="B44-cancers-11-01668"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sticht</surname><given-names>C.</given-names></name><name><surname>De La Torre</surname><given-names>C.</given-names></name><name><surname>Parveen</surname><given-names>A.</given-names></name><name><surname>Gretz</surname><given-names>N.</given-names></name></person-group><article-title>miRWalk: An online resource for prediction of microRNA binding sites</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0206239</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0206239</pub-id><pub-id pub-id-type="pmid">30335862</pub-id></element-citation></ref><ref id="B45-cancers-11-01668"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>Z.</given-names></name><name><surname>Cui</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>TransmiR v2.0: An updated transcription factor-microRNA regulation database</article-title><source>Nucleic Acids Res.</source><year>2019</year><volume>47</volume><fpage>D253</fpage><lpage>D258</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1023</pub-id><pub-id pub-id-type="pmid">30371815</pub-id></element-citation></ref><ref id="B46-cancers-11-01668"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsico</surname><given-names>A.</given-names></name><name><surname>Huska</surname><given-names>M.R.</given-names></name><name><surname>Lasserre</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Vucicevic</surname><given-names>D.</given-names></name><name><surname>Musahl</surname><given-names>A.</given-names></name><name><surname>Orom</surname><given-names>U.</given-names></name><name><surname>Vingron</surname><given-names>M.</given-names></name></person-group><article-title>PROmiRNA: A new miRNA promoter recognition method uncovers the complex regulation of intronic miRNAs</article-title><source>Genome Biol.</source><year>2013</year><volume>14</volume><fpage>R84</fpage><pub-id pub-id-type="doi">10.1186/gb-2013-14-8-r84</pub-id><pub-id pub-id-type="pmid">23958307</pub-id></element-citation></ref><ref id="B47-cancers-11-01668"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>Y.H.</given-names></name><name><surname>Hwang</surname><given-names>S.Y.</given-names></name><name><surname>Lee</surname><given-names>Y.S.</given-names></name><name><surname>Shin</surname><given-names>S.M.</given-names></name><name><surname>Hwang</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>Y.W.</given-names></name><name><surname>Jang</surname><given-names>S.W.</given-names></name><name><surname>Ryoo</surname><given-names>Z.Y.</given-names></name><etal/></person-group><article-title>Identification and differential expression of novel human cervical cancer oncogene HCCR-2 in human cancers and its involvement in p53 stabilization</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>4679</fpage><lpage>4689</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1206624</pub-id><pub-id pub-id-type="pmid">12879013</pub-id></element-citation></ref><ref id="B48-cancers-11-01668"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>K.</given-names></name><name><surname>Maruyama</surname><given-names>Z.</given-names></name><name><surname>Sakai</surname><given-names>A.</given-names></name><name><surname>Izumi</surname><given-names>S.</given-names></name><name><surname>Moriishi</surname><given-names>T.</given-names></name><name><surname>Yoshida</surname><given-names>C.A.</given-names></name><name><surname>Miyazaki</surname><given-names>T.</given-names></name><name><surname>Komori</surname><given-names>H.</given-names></name><name><surname>Takada</surname><given-names>K.</given-names></name><name><surname>Kawaguchi</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Overexpression of Cdk6 and Ccnd1 in chondrocytes inhibited chondrocyte maturation and caused p53-dependent apoptosis without enhancing proliferation</article-title><source>Oncogene</source><year>2014</year><volume>33</volume><fpage>1862</fpage><lpage>1871</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.130</pub-id><pub-id pub-id-type="pmid">23624920</pub-id></element-citation></ref><ref id="B49-cancers-11-01668"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lever</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>E.Y.</given-names></name><name><surname>Grewal</surname><given-names>J.</given-names></name><name><surname>Jones</surname><given-names>M.R.</given-names></name><name><surname>Jones</surname><given-names>S.J.M.</given-names></name></person-group><article-title>CancerMine: A literature-mined resource for drivers, oncogenes and tumor suppressors in cancer</article-title><source>Nat. Methods</source><year>2019</year><volume>16</volume><fpage>505</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1038/s41592-019-0422-y</pub-id><pub-id pub-id-type="pmid">31110280</pub-id></element-citation></ref><ref id="B50-cancers-11-01668"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabant</surname><given-names>M.</given-names></name><name><surname>Amrouche</surname><given-names>L.</given-names></name><name><surname>Morin</surname><given-names>L.</given-names></name><name><surname>Bonifay</surname><given-names>R.</given-names></name><name><surname>Lebreton</surname><given-names>X.</given-names></name><name><surname>Aouni</surname><given-names>L.</given-names></name><name><surname>Benon</surname><given-names>A.</given-names></name><name><surname>Sauvaget</surname><given-names>V.</given-names></name><name><surname>Le Vaillant</surname><given-names>L.</given-names></name><name><surname>Aulagnon</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Early Low Urinary CXCL9 and CXCL10 Might Predict Immunological Quiescence in Clinically and Histologically Stable Kidney Recipients</article-title><source>Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant. Surg.</source><year>2016</year><volume>16</volume><fpage>1868</fpage><lpage>1881</lpage><pub-id pub-id-type="doi">10.1111/ajt.13677</pub-id></element-citation></ref><ref id="B51-cancers-11-01668"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rawal</surname><given-names>R.M.</given-names></name><name><surname>Joshi</surname><given-names>M.N.</given-names></name><name><surname>Bhargava</surname><given-names>P.</given-names></name><name><surname>Shaikh</surname><given-names>I.</given-names></name><name><surname>Pandit</surname><given-names>A.S.</given-names></name><name><surname>Patel</surname><given-names>R.P.</given-names></name><name><surname>Patel</surname><given-names>S.</given-names></name><name><surname>Kothari</surname><given-names>K.</given-names></name><name><surname>Shah</surname><given-names>M.</given-names></name><name><surname>Saxena</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Tobacco habituated and non-habituated subjects exhibit different mutational spectrums in head and neck squamous cell carcinoma</article-title><source>3 Biotech.</source><year>2015</year><volume>5</volume><fpage>685</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1007/s13205-014-0267-0</pub-id></element-citation></ref><ref id="B52-cancers-11-01668"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rupp</surname><given-names>L.J.</given-names></name><name><surname>Brady</surname><given-names>B.L.</given-names></name><name><surname>Carpenter</surname><given-names>A.C.</given-names></name><name><surname>De Obaldia</surname><given-names>M.E.</given-names></name><name><surname>Bhandoola</surname><given-names>A.</given-names></name><name><surname>Bosselut</surname><given-names>R.</given-names></name><name><surname>Muljo</surname><given-names>S.A.</given-names></name><name><surname>Bassing</surname><given-names>C.H.</given-names></name></person-group><article-title>The microRNA biogenesis machinery modulates lineage commitment during alphabeta T cell development</article-title><source>J. Immunol.</source><year>2014</year><volume>193</volume><fpage>4032</fpage><lpage>4042</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1401359</pub-id><pub-id pub-id-type="pmid">25217159</pub-id></element-citation></ref><ref id="B53-cancers-11-01668"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavali</surname><given-names>S.</given-names></name><name><surname>Bruhn</surname><given-names>S.</given-names></name><name><surname>Tiemann</surname><given-names>K.</given-names></name><name><surname>Saetrom</surname><given-names>P.</given-names></name><name><surname>Barrenas</surname><given-names>F.</given-names></name><name><surname>Saito</surname><given-names>T.</given-names></name><name><surname>Kanduri</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Benson</surname><given-names>M.</given-names></name></person-group><article-title>MicroRNAs act complementarily to regulate disease-related mRNA modules in human diseases</article-title><source>RNA</source><year>2013</year><volume>19</volume><fpage>1552</fpage><lpage>1562</lpage><pub-id pub-id-type="doi">10.1261/rna.038414.113</pub-id><pub-id pub-id-type="pmid">24062574</pub-id></element-citation></ref><ref id="B54-cancers-11-01668"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Xia</surname><given-names>S.</given-names></name><name><surname>Xing</surname><given-names>C.</given-names></name><name><surname>Ci</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>R.</given-names></name><name><surname>Tian</surname><given-names>S.</given-names></name><name><surname>Ma</surname><given-names>G.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>KLF5 activates microRNA 200 transcription to maintain epithelial characteristics and prevent induced epithelial-mesenchymal transition in epithelial cells</article-title><source>Mol. Cell. Biol.</source><year>2013</year><volume>33</volume><fpage>4919</fpage><lpage>4935</lpage><pub-id pub-id-type="doi">10.1128/MCB.00787-13</pub-id><pub-id pub-id-type="pmid">24126055</pub-id></element-citation></ref><ref id="B55-cancers-11-01668"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellwanger</surname><given-names>D.C.</given-names></name><name><surname>Leonhardt</surname><given-names>J.F.</given-names></name><name><surname>Mewes</surname><given-names>H.W.</given-names></name></person-group><article-title>Large-scale modeling of condition-specific gene regulatory networks by information integration and inference</article-title><source>Nucleic Acids Res.</source><year>2014</year><volume>42</volume><fpage>e166</fpage><pub-id pub-id-type="doi">10.1093/nar/gku916</pub-id><pub-id pub-id-type="pmid">25294837</pub-id></element-citation></ref><ref id="B56-cancers-11-01668"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Jiang</surname><given-names>P.</given-names></name><name><surname>Chan</surname><given-names>L.K.</given-names></name><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Kwong</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A novel miR-193a-5p-YY1-APC regulatory axis in human endometrioid endometrial adenocarcinoma</article-title><source>Oncogene</source><year>2013</year><volume>32</volume><fpage>3432</fpage><lpage>3442</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.360</pub-id><pub-id pub-id-type="pmid">22907428</pub-id></element-citation></ref><ref id="B57-cancers-11-01668"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Tan</surname><given-names>Z.</given-names></name><name><surname>Wei</surname><given-names>W.</given-names></name><name><surname>Yan</surname><given-names>B.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>K.</given-names></name><name><surname>Yang</surname><given-names>A.</given-names></name><etal/></person-group><article-title>MicroRNA-26a is a key regulon that inhibits progression and metastasis of c-Myc/EZH2 double high advanced hepatocellular carcinoma</article-title><source>Cancer Lett.</source><year>2018</year><volume>426</volume><fpage>98</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2018.04.005</pub-id><pub-id pub-id-type="pmid">29653269</pub-id></element-citation></ref><ref id="B58-cancers-11-01668"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sokol</surname><given-names>E.</given-names></name><name><surname>Kedzierska</surname><given-names>H.</given-names></name><name><surname>Czubaty</surname><given-names>A.</given-names></name><name><surname>Rybicka</surname><given-names>B.</given-names></name><name><surname>Rodzik</surname><given-names>K.</given-names></name><name><surname>Tanski</surname><given-names>Z.</given-names></name><name><surname>Boguslawska</surname><given-names>J.</given-names></name><name><surname>Piekielko-Witkowska</surname><given-names>A.</given-names></name></person-group><article-title>microRNA-mediated regulation of splicing factors SRSF1, SRSF2 and hnRNP A1 in context of their alternatively spliced 3&#x02032;UTRs</article-title><source>Exp. Cell Res.</source><year>2018</year><volume>363</volume><fpage>208</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2018.01.009</pub-id><pub-id pub-id-type="pmid">29331391</pub-id></element-citation></ref><ref id="B59-cancers-11-01668"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Zhan</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>B.</given-names></name></person-group><article-title>miR-335 inhibits the proliferation and invasion of clear cell renal cell carcinoma cells through direct suppression of BCL-W</article-title><source>Tumour Biol. J. Int. Soc. Oncodev. Biol. Med.</source><year>2015</year><volume>36</volume><fpage>6875</fpage><lpage>6882</lpage><pub-id pub-id-type="doi">10.1007/s13277-015-3382-6</pub-id></element-citation></ref><ref id="B60-cancers-11-01668"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>Q.</given-names></name><name><surname>Sun</surname><given-names>H.F.</given-names></name><name><surname>Wang</surname><given-names>W.J.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Ding</surname><given-names>J.</given-names></name><name><surname>Di</surname><given-names>W.</given-names></name></person-group><article-title>miRNA-365b promotes hepatocellular carcinoma cell migration and invasion by downregulating SGTB</article-title><source>Future Oncol.</source><year>2019</year><volume>15</volume><fpage>2019</fpage><lpage>2028</lpage><pub-id pub-id-type="doi">10.2217/fon-2018-0676</pub-id><pub-id pub-id-type="pmid">30943053</pub-id></element-citation></ref><ref id="B61-cancers-11-01668"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hildebrandt</surname><given-names>M.A.</given-names></name><name><surname>Gu</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>J.</given-names></name><name><surname>Ye</surname><given-names>Y.</given-names></name><name><surname>Tan</surname><given-names>W.</given-names></name><name><surname>Tamboli</surname><given-names>P.</given-names></name><name><surname>Wood</surname><given-names>C.G.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name></person-group><article-title>Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma</article-title><source>Oncogene</source><year>2010</year><volume>29</volume><fpage>5724</fpage><lpage>5728</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.305</pub-id><pub-id pub-id-type="pmid">20676129</pub-id></element-citation></ref><ref id="B62-cancers-11-01668"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>R.H.</given-names></name><name><surname>Yu</surname><given-names>D.J.</given-names></name><name><surname>Zhong</surname><given-names>M.</given-names></name></person-group><article-title>MiR-1269a acts as an onco-miRNA in non-small cell lung cancer via down-regulating SOX6</article-title><source>Eur. Rev. Med. Pharmacol. Sci.</source><year>2018</year><volume>22</volume><fpage>4888</fpage><lpage>4897</lpage><pub-id pub-id-type="doi">10.26355/eurrev_201808_15625</pub-id><pub-id pub-id-type="pmid">30070324</pub-id></element-citation></ref><ref id="B63-cancers-11-01668"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bu</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>K.Y.</given-names></name><name><surname>Rakhilin</surname><given-names>N.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Closa</surname><given-names>A.</given-names></name><name><surname>Tung</surname><given-names>K.L.</given-names></name><name><surname>King</surname><given-names>S.</given-names></name><name><surname>Kristine Varanko</surname><given-names>A.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>miR-1269 promotes metastasis and forms a positive feedback loop with TGF-beta</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>6879</fpage><pub-id pub-id-type="doi">10.1038/ncomms7879</pub-id><pub-id pub-id-type="pmid">25872451</pub-id></element-citation></ref><ref id="B64-cancers-11-01668"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowak</surname><given-names>I.</given-names></name><name><surname>Boratyn</surname><given-names>E.</given-names></name><name><surname>Durbas</surname><given-names>M.</given-names></name><name><surname>Horwacik</surname><given-names>I.</given-names></name><name><surname>Rokita</surname><given-names>H.</given-names></name></person-group><article-title>Exogenous expression of miRNA-3613-3p causes APAF1 downregulation and affects several proteins involved in apoptosis in BE(2)-C human neuroblastoma cells</article-title><source>Int. J. Oncol.</source><year>2018</year><volume>53</volume><fpage>1787</fpage><lpage>1799</lpage><pub-id pub-id-type="doi">10.3892/ijo.2018.4509</pub-id><pub-id pub-id-type="pmid">30066861</pub-id></element-citation></ref><ref id="B65-cancers-11-01668"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srinivasan</surname><given-names>G.</given-names></name><name><surname>Williamson</surname><given-names>E.A.</given-names></name><name><surname>Kong</surname><given-names>K.</given-names></name><name><surname>Jaiswal</surname><given-names>A.S.</given-names></name><name><surname>Huang</surname><given-names>G.</given-names></name><name><surname>Kim</surname><given-names>H.S.</given-names></name><name><surname>Scharer</surname><given-names>O.</given-names></name><name><surname>Zhao</surname><given-names>W.</given-names></name><name><surname>Burma</surname><given-names>S.</given-names></name><name><surname>Sung</surname><given-names>P.</given-names></name><etal/></person-group><article-title>MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2019</year><volume>116</volume><fpage>17438</fpage><lpage>17443</lpage><pub-id pub-id-type="doi">10.1073/pnas.1903150116</pub-id><pub-id pub-id-type="pmid">31395736</pub-id></element-citation></ref><ref id="B66-cancers-11-01668"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chai</surname><given-names>B.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Cui</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Suo</surname><given-names>Y.</given-names></name><name><surname>Dou</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name></person-group><article-title>MiR-223-3p promotes the proliferation, invasion and migration of colon cancer cells by negative regulating PRDM1</article-title><source>Am. J. Transl. Res.</source><year>2019</year><volume>11</volume><fpage>4516</fpage><lpage>4523</lpage><pub-id pub-id-type="pmid">31396355</pub-id></element-citation></ref><ref id="B67-cancers-11-01668"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>N.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>N.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name></person-group><article-title>Gene expression profiling and bioinformatics analysis of gastric carcinoma</article-title><source>Exp. Mol. Pathol.</source><year>2014</year><volume>96</volume><fpage>361</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1016/j.yexmp.2014.02.007</pub-id><pub-id pub-id-type="pmid">24589858</pub-id></element-citation></ref><ref id="B68-cancers-11-01668"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Nagabayashi</surname><given-names>G.</given-names></name><name><surname>Seeger</surname><given-names>R.C.</given-names></name><name><surname>Gatti</surname><given-names>R.A.</given-names></name></person-group><article-title>ATM is down-regulated by N-Myc-regulated microRNA-421</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>1506</fpage><lpage>1511</lpage><pub-id pub-id-type="doi">10.1073/pnas.0907763107</pub-id><pub-id pub-id-type="pmid">20080624</pub-id></element-citation></ref><ref id="B69-cancers-11-01668"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>R.</given-names></name><name><surname>Garg</surname><given-names>A.</given-names></name><name><surname>Benny Malgulwar</surname><given-names>P.</given-names></name><name><surname>Sharma</surname><given-names>V.</given-names></name><name><surname>Sarkar</surname><given-names>C.</given-names></name><name><surname>Kulshreshtha</surname><given-names>R.</given-names></name></person-group><article-title>p53 and miR-210 regulated NeuroD2, a neuronal basic helix-loop-helix transcription factor, is downregulated in glioblastoma patients and functions as a tumor suppressor under hypoxic microenvironment</article-title><source>Int. J. Cancer</source><year>2018</year><volume>142</volume><fpage>1817</fpage><lpage>1828</lpage><pub-id pub-id-type="doi">10.1002/ijc.31209</pub-id><pub-id pub-id-type="pmid">29226333</pub-id></element-citation></ref><ref id="B70-cancers-11-01668"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Kim</surname><given-names>I.K.</given-names></name><name><surname>Sun</surname><given-names>P.</given-names></name><name><surname>Gupta</surname><given-names>S.</given-names></name></person-group><article-title>NF-kappaB mediated miR-21 regulation in cardiomyocytes apoptosis under oxidative stress</article-title><source>Free Radic. Res.</source><year>2014</year><volume>48</volume><fpage>282</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.3109/10715762.2013.865839</pub-id><pub-id pub-id-type="pmid">24237305</pub-id></element-citation></ref><ref id="B71-cancers-11-01668"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groenendyk</surname><given-names>J.</given-names></name><name><surname>Peng</surname><given-names>Z.</given-names></name><name><surname>Dudek</surname><given-names>E.</given-names></name><name><surname>Fan</surname><given-names>X.</given-names></name><name><surname>Mizianty</surname><given-names>M.J.</given-names></name><name><surname>Dufey</surname><given-names>E.</given-names></name><name><surname>Urra</surname><given-names>H.</given-names></name><name><surname>Sepulveda</surname><given-names>D.</given-names></name><name><surname>Rojas-Rivera</surname><given-names>D.</given-names></name><name><surname>Lim</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Interplay between the oxidoreductase PDIA6 and microRNA-322 controls the response to disrupted endoplasmic reticulum calcium homeostasis</article-title><source>Sci. Signal.</source><year>2014</year><volume>7</volume><fpage>ra54</fpage><pub-id pub-id-type="doi">10.1126/scisignal.2004983</pub-id><?supplied-pmid 24917591?><pub-id pub-id-type="pmid">24917591</pub-id></element-citation></ref><ref id="B72-cancers-11-01668"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>R.</given-names></name><name><surname>Gregory</surname><given-names>P.A.</given-names></name><name><surname>Fernandes</surname><given-names>R.C.</given-names></name><name><surname>Denis</surname><given-names>I.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Townley</surname><given-names>S.L.</given-names></name><name><surname>Zhao</surname><given-names>S.G.</given-names></name><name><surname>Hanson</surname><given-names>A.R.</given-names></name><name><surname>Pickering</surname><given-names>M.A.</given-names></name><name><surname>Armstrong</surname><given-names>H.K.</given-names></name><etal/></person-group><article-title>MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2</article-title><source>Cancer Res.</source><year>2017</year><volume>77</volume><fpage>1021</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-2529</pub-id><?supplied-pmid 28011622?><pub-id pub-id-type="pmid">28011622</pub-id></element-citation></ref><ref id="B73-cancers-11-01668"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Xu</surname><given-names>T.</given-names></name><name><surname>Qiu</surname><given-names>P.</given-names></name><name><surname>Xu</surname><given-names>G.</given-names></name></person-group><article-title>Caveolin-1 promotes pituitary adenoma cells migration and invasion by regulating the interaction between EGR1 and KLF5</article-title><source>Exp. Cell Res.</source><year>2018</year><volume>367</volume><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2018.01.008</pub-id><?supplied-pmid 29309750?><pub-id pub-id-type="pmid">29309750</pub-id></element-citation></ref><ref id="B74-cancers-11-01668"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>W.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Kwon</surname><given-names>D.</given-names></name><name><surname>Chun</surname><given-names>J.</given-names></name><name><surname>Son</surname><given-names>B.</given-names></name><name><surname>Kim</surname><given-names>E.</given-names></name><name><surname>Lee</surname><given-names>J.M.</given-names></name><name><surname>Youn</surname><given-names>H.</given-names></name><name><surname>Youn</surname><given-names>B.</given-names></name></person-group><article-title>TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation</article-title><source>Oncogene</source><year>2017</year><volume>36</volume><fpage>1585</fpage><lpage>1596</lpage><pub-id pub-id-type="doi">10.1038/onc.2016.328</pub-id><?supplied-pmid 27593936?><pub-id pub-id-type="pmid">27593936</pub-id></element-citation></ref><ref id="B75-cancers-11-01668"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>R.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Xiao</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Liang</surname><given-names>Y.</given-names></name></person-group><article-title>Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2012</year><volume>425</volume><fpage>368</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2012.07.098</pub-id><pub-id pub-id-type="pmid">22842456</pub-id></element-citation></ref><ref id="B76-cancers-11-01668"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>L.G.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>Q.Y.</given-names></name></person-group><article-title>clusterProfiler: An R package for comparing biological themes among gene clusters</article-title><source>Om. A J. Integr. Biol.</source><year>2012</year><volume>16</volume><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id></element-citation></ref><ref id="B77-cancers-11-01668"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>P.</given-names></name><name><surname>Markiel</surname><given-names>A.</given-names></name><name><surname>Ozier</surname><given-names>O.</given-names></name><name><surname>Baliga</surname><given-names>N.S.</given-names></name><name><surname>Wang</surname><given-names>J.T.</given-names></name><name><surname>Ramage</surname><given-names>D.</given-names></name><name><surname>Amin</surname><given-names>N.</given-names></name><name><surname>Schwikowski</surname><given-names>B.</given-names></name><name><surname>Ideker</surname><given-names>T.</given-names></name></person-group><article-title>Cytoscape: A software environment for integrated models of biomolecular interaction networks</article-title><source>Genome Res.</source><year>2003</year><volume>13</volume><fpage>2498</fpage><lpage>2504</lpage><pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id><pub-id pub-id-type="pmid">14597658</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="cancers-11-01668-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p><bold>The forest plots of hazard ratios (HR) of top 21 most significant survival associated miRNAs in ccRCC (<italic>p</italic>-value &#x0003c; 0.001).</bold> Red represents the risk factors (HR &#x0003e; 1) and blue represents protective factors (HR &#x0003c; 1).</p></caption><graphic xlink:href="cancers-11-01668-g001"/></fig><fig id="cancers-11-01668-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p><bold>Kaplan Meier survival based on the expression level of eight miRNAs.</bold> Overall survival curves for high-expression and low-expression ccRCC patient cohorts. (<bold>A</bold>): hsa-miR-1269a; (<bold>B</bold>): hsa-miR-183-5p; (<bold>C</bold>): hsa-miR-9-5p; (<bold>D</bold>): hsa-miR-335-3p; (<bold>E</bold>): hsa-miR-3613-5p; (<bold>F</bold>): hsa-miR-223-3p; (<bold>G</bold>): hsa-miR-365b-3p; and, (<bold>H</bold>): hsa-miR-144-5p.</p></caption><graphic xlink:href="cancers-11-01668-g002"/></fig><fig id="cancers-11-01668-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p><bold>Kaplan Meier survival and receiver operating characteristic (ROC) curves based on the riskscore of the eight-miRNA signature.</bold> (<bold>A</bold>): Overall survival curves of high-risk and low-risk based on the eight-miRNA signature model. (<bold>B</bold>): Receiver operating characteristic (ROC) curves for high and low risk from the eight-miRNA signature model.</p></caption><graphic xlink:href="cancers-11-01668-g003"/></fig><fig id="cancers-11-01668-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p><bold>The cancer signaling pathway and protein network analysis of these up-regulated targets and the prognostic model of the ten-hub gene signature</bold>. (<bold>A</bold>): Target genes of four down-regulated miRNAs involve in the network map of cancer-related signaling pathways. The green represents the down-regulated expression and the red represents up-regulated expression; (<bold>B</bold>): Target protein interaction network of four down-regulated miRNAs. The blue line means low credibility and the purple line means high credibility; (<bold>C</bold>): Overall survival curves for high-risk and low-risk groups based on the ten-hub gene model; and, (<bold>D</bold>): ROC curves for high-risk and low-risk based on the ten-hub gene model.</p></caption><graphic xlink:href="cancers-11-01668-g004"/></fig><fig id="cancers-11-01668-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p><bold>The heat map of down-regulated targets of three up-regulated miRNAs involve in cancer-related signaling pathway and the prognostic model of the five-gene signature</bold>. (<bold>A</bold>): The heat map of these down-regulated targets regulated by has-miR-3613-5p, has-miR-223-3p, and has-miR-365b-3p involved in cancer-related signaling pathways; (<bold>B</bold>): Overall survival curves for high-risk and low-risk groups based on the prognostic model of a five-gene signature; (<bold>C</bold>): ROC curves for high and low risk from the prognostic model of a five-gene signature.</p></caption><graphic xlink:href="cancers-11-01668-g005"/></fig><fig id="cancers-11-01668-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p><bold>Kaplan Meier survival and ROC curves based on the risk score of five prognostic targets of has-miR-144-5p.</bold> (<bold>A</bold>): Overall survival curves for high-risk and low-risk groups based on the prognostic model of a five-gene signature; (<bold>B</bold>): ROC curves for high and low risk from the prognostic model of a five-gene signature.</p></caption><graphic xlink:href="cancers-11-01668-g006"/></fig><fig id="cancers-11-01668-f007" orientation="portrait" position="float"><label>Figure 7</label><caption><p><bold>The interplay network between twenty-two transcription factors and eight miRNAs.</bold> The circle represents the miRNA and the diamond represents the transcription factor. The blue represents a down-regulation expression and the purple represents an up-regulation expression. The sharp arrow represents activation and the flat arrow represents inhibition.</p></caption><graphic xlink:href="cancers-11-01668-g007"/></fig><fig id="cancers-11-01668-f008" orientation="portrait" position="float"><label>Figure 8</label><caption><p><bold>Kaplan Meier survival and ROC curves based on the risk score of the combined nine transcription factors as a signature.</bold> (<bold>A</bold>): Overall survival curves for high-risk and low-risk groups based on the prognostic model of a nine-TF signature; (<bold>B</bold>): ROC curves for high and low risk from the prognostic model of a nine-TF signature.</p></caption><graphic xlink:href="cancers-11-01668-g008"/></fig><fig id="cancers-11-01668-f009" orientation="portrait" position="float"><label>Figure 9</label><caption><p><bold>Kaplan Meier survival and ROC curves based on the risk score of the combined five transcription factors and six miRNAs as a signature.</bold> (<bold>A</bold>): Overall survival curves for high-risk and low-risk groups based on the prognostic model of an eleven-gene signature; and, (<bold>B</bold>): ROC curves for high and low risk from the prognostic model of an eleven-gene signature.</p></caption><graphic xlink:href="cancers-11-01668-g009"/></fig><fig id="cancers-11-01668-f010" orientation="portrait" position="float"><label>Figure 10</label><caption><p><bold>The molecular mechanism of the interplay between transcription factors and miRNAs improving the prognosis of ccRCC patients.</bold> The red represents an up-regulation of gene expression and the green represents down-regulation of gene expression. The sharp arrow represents activation and the flat arrow represents inhibition.</p></caption><graphic xlink:href="cancers-11-01668-g010"/></fig><table-wrap id="cancers-11-01668-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">cancers-11-01668-t001_Table 1</object-id><label>Table 1</label><caption><p>Univariate and multivariate Cox regression analysis of the overall survival for clinical factors and risk of the combined eight prognostic miRNAs as a signature.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin" colspan="1">Variables</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Univariate Analysis</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Multivariate Analysis</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">Hazard Ratio (95% CI)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic>-Value</th><th align="center" valign="middle" rowspan="1" colspan="1">Hazard Ratio (95% CI)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic>-Value</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Age</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">1.029 (1.014&#x02013;1.043)</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">1.028 (1.012&#x02013;1.044)</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gender</td><td align="center" valign="middle" rowspan="1" colspan="1">0.920 (0.660&#x02013;1.284)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.624</td><td align="center" valign="middle" rowspan="1" colspan="1">0.832 (0.590&#x02013;1.172)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.292 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tumor_pathologic_T</td><td align="center" valign="middle" rowspan="1" colspan="1">1.855 (1.556&#x02013;2.211)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.816 (0.525&#x02013;1.269)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.367 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Metastasis_pathologic_M</td><td align="center" valign="middle" rowspan="1" colspan="1">4.671 (3.369&#x02013;6.475)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.514 (0.744&#x02013;3.078)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.253 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pathologic_stage_Stage</td><td align="center" valign="middle" rowspan="1" colspan="1">1.884 (1.634&#x02013;2.172)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.605 (0.994&#x02013;2.590)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.053 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Histologic_grade_G</td><td align="center" valign="middle" rowspan="1" colspan="1">2.238 (1.800&#x02013;2.783)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.275 (0.996&#x02013;1.633)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.054 </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The eight-miRNA signature</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.009 (2.725&#x02013;5.898)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.666 (1.768&#x02013;4.020)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>Age, gender, tumor stage, metastasis pathologic, pathologic stage, histologic grade, and the eight-miRNA signature were coded as continuous variable. Specifically, pathologic stage was coded as I = 1, II = 2, III = 3, IV = 4. Tumor stage was coded as T1 = 1, T2 = 2, T3 = 3, T4 = 4. Histologic grade was coded as G1 = 1, G2 = 2, G3 = 3, G4 = 4.</p></fn></table-wrap-foot></table-wrap><table-wrap id="cancers-11-01668-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">cancers-11-01668-t002_Table 2</object-id><label>Table 2</label><caption><p>Univariate and multivariate Cox regression analysis of overall survival for clinical factors and risk of the combined five prognostic transcription factors and six miRNAs as a signature.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Variables</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Univariate Analysis</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Multivariate Analysis</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hazard Ratio (95% CI)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic>-Value </th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hazard Ratio (95% CI) </th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic>-Value </th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age</td><td align="center" valign="middle" rowspan="1" colspan="1">1.029 (1.014&#x02013;1.043)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.028 (1.011&#x02013;1.044)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gender</td><td align="center" valign="middle" rowspan="1" colspan="1">0.920 (0.6595&#x02013;1.284)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.624</td><td align="center" valign="middle" rowspan="1" colspan="1">0.949 (0.673&#x02013;1.338)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.765 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tumor_pathologic_T</td><td align="center" valign="middle" rowspan="1" colspan="1">1.855 (1.556&#x02013;2.211)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.840 (0.539&#x02013;1.311)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.443 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Metastasis_pathologic_M</td><td align="center" valign="middle" rowspan="1" colspan="1">4.671 (3.369&#x02013;6.475)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.707 (0.830&#x02013;3.513)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.146 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pathologic_stage_Stage</td><td align="center" valign="middle" rowspan="1" colspan="1">1.884 (1.634&#x02013;2.172)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.410 (0.865&#x02013;2.300)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.178 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Histologic_grade_G</td><td align="center" valign="middle" rowspan="1" colspan="1">2.238 (1.800&#x02013;2.783)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.420 (1.118&#x02013;1.803)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.765 </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The eleven-gene signature</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.349 (2.943&#x02013;6.428)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.590 (1.706&#x02013;3.930)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>Age, gender, tumor stage, metastasis pathologic, pathologic stage, histologic grade and the eleven-gene signature were coded as continuous variable. Specifically, pathologic stage was coded as I = 1, II = 2, III = 3, IV = 4. Tumor stage was coded as T1 = 1, T2 = 2, T3 = 3, T4 = 4. Histologic grade was coded as G1 = 1, G2 = 2, G3 = 3, G4 = 4.</p></fn></table-wrap-foot></table-wrap></floats-group></article>